Cryosite Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Cryosite Limited
ABN:	86 090 919 476
Reporting period:	For the year ended 30 June 2026
Previous period:	For the year ended 30 June 2025
Reporting Currency:	Australian Dollars

2. Results for announcement to the market

	2026 $'000	2025 $'000	Change $'000	Change %
Revenue from ordinary activities	16,700	14,116	2,584	18%
Profit before tax for the period from ordinary activities	3,154	2,523	631	25%
Profit from ordinary activities after tax attributable to members	2,235	1,884	351	19%

The profit for the Group after providing for income tax amounted to $2,235,000 (30 June 2025: $1,884,000).

Commentary on the results to the market
Results for the year ended 30 June 2026 reflect a strengthening of trading conditions in the financial year.

- *Revenue of $16,700,000, up 18%.*
- *Gross profit of $10,425,000, up 17%.*
- *Earnings before interest, tax, depreciation and amortisation (EBITDA) of $4,289,000, up 27%.*
- *Earnings before interest and tax (EBIT) of $3,377,000, up 35%.*
- *Net Profit of $2,235,000, up 19%. The Group had a higher profit (25% up) and $124k Income tax expense tax adjustment that related to $217k Non-Operational Income for R&D claim FY25, resulting in income tax expense of $919,000 in FY26, an increase of $280,000 (44%) on the prior period.*

Dividends
The Board resolved not to declare a dividend for FY26. The Group utilised operating cash flows and competitively priced debt to successfully complete the acquisition of a secondary warehouse facility at Auburn NSW in November 2025, which doubled our storage capacity to accommodate future growth.

A further explanation of the result of the current period is set out in the Directors' Report contained in the attached Annual Financial report.

The Directors consider Earnings Before Interest and Tax ('EBIT') and Earnings Before Interest, Tax, Depreciation and Amortisation ('EBITDA') to reflect the core earnings of the Group. EBIT and EBITDA are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the profit under AAS adjusted for non-cash and significant items. The Group's reconciliation of its statutory net profit after tax ('NPAT') for the current and previous year to EBIT and EBITDA is as follows:

	Consolidated 2026 $'000	Consolidated 2025 $'000
Net profit after tax	2,235	1,884
Add: Income tax expense	919	639
Add: Interest expense	336	150
Less: Interest revenue calculated using effective interest method	(113)	(177)
EBIT	**3,377**	**2,496**
Add: Depreciation and amortisation expense	912	871
EBITDA	**4,289**	**3,367**

For personal use only

Cryosite Limited
Appendix 4E
Preliminary final report

3. Net tangible assets backing

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	10.58	5.44

The calculation of net tangible assets excludes right-of-use assets, intangible assets, and lease liabilities.

4. Dividends

Current period
There were no dividends paid, recommended or declared during the current financial period.

Previous period

	Amount per security Cents	Franked amount per security Cents
Final unfranked dividend for the year ended 30 June 2024	2.00	-

5. Audit qualification or review

The financial statements have been audited and an unmodified opinion has been issued.

6. Attachments

The Annual Report of Cryosite Limited for the year ended 30 June 2026 is attached.

7. Signed

Signed Mark Kerr Date: 18 August 2026

Mark Kerr
Non-Executive Chairman

For personal use only

For personal use only

cryosite
your scientific partner

Annual Report - June 2026





Cryosite Limited
Contents
30 June 2026

Corporate directory	3
Directors' report	4
Auditor's independence declaration	24
Consolidated statement of profit or loss and other comprehensive income	25
Consolidated statement of financial position	26
Consolidated statement of changes in equity	27
Consolidated statement of cash flows	28
Notes to the consolidated financial statements	29
Consolidated entity disclosure statement	59
Directors' declaration	60
Independent auditor's report to the members of Cryosite Limited	61
Shareholder information	65
Back page	66

For personal use only

Cryosite Limited
Corporate directory
30 June 2026

Directors	Mark Kerr (Non-Executive Chairman) Andrew Kerr (Executive Director) Scott Thomas (Non-Executive Director)
Company secretary	Hamish George
Notice of annual general meeting	The details of the annual general meeting of Cryosite Limited are yet to be announced.
Registered office	13a Ferndell Street South Granville NSW 2142 Tel: +61 2 8865 2000 Email: corporate@cryosite.com
Principal place of business	13a Ferndell Street South Granville NSW 2142
Share register	Automic Group Level 5, 126 Phillip Street Sydney NSW, 2000
Auditor	Forvis Mazars Audit & Assurance Pty Limited Level 5, 600 Bourke Street Melbourne Vic 3000
Stock exchange listing	Cryosite Limited shares are listed on the Australian Securities Exchange (ASX code: CTE)
Website	www.cryosite.com www.cryosite.com.au
Corporate Governance Statement	The Directors and management are committed to conducting the business of Cryosite Limited in an ethical manner and in accordance with the highest standards of corporate governance. Cryosite Limited has adopted and substantially complied with the ASX Corporate Governance Principles and Recommendations (Fourth Edition) (`Recommendations') to the extent appropriate to the size and nature of its operations. The Corporate Governance Statement, which sets out the corporate governance practices that were in operation during the financial year and identifies and explains any Recommendations that have not been followed, was approved by the Board of Directors at the same time as the Annual Report and can be found on the ASX's website at: https://www.asx.com.au/markets/company/CTE

For personal use only

For personal use only

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'Group') consisting of Cryosite Limited (referred to hereafter as 'Cryosite', the 'Company' or 'parent entity') and the entities it controlled at the end of, or during, the year ended 30 June 2026.

Directors

The following persons were directors of Cryosite Limited during the whole of the financial year and up to the date of this report, unless otherwise stated:

Mark Kerr	Non-Executive Chairman
Andrew Kerr	Executive Director
Scott Thomas	Non-Executive Director

Dividends

Dividends paid during the financial year were as follows:

	Consolidated 2026 $'000	Consolidated 2025 $'000
Final unfranked dividend for the year ended 30 June 2026 of 0 cents (2025: paid 2 cents final unfranked dividend for the year ended 30 June 2024) per ordinary share	-	976

Principal activities

Cryosite provides specialised, temperature-controlled logistics and depot services, including secure storage, labelling, secondary packaging, import/export coordination, inventory management, distribution, destruction, and reverse logistics.

The Group supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Advanced Therapy Medicinal Products (ATMPs), Research and Development (R&D) materials, and medical devices.

Services are structured around the following temperature-controlled storage and distribution capabilities:

(1) **Ambient (15°C to 25°C), cold (2°C to 8°C), and frozen (-20°C):** Storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions. This includes Good Manufacturing Practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements.

(2) **Ultra-frozen (-80°C) and cryogenic (<-150°C):** Specialised handling of materials requiring Ultra-Frozen or Cryogenic conditions, including Advanced Therapy Medicinal Products (ATMPs), such as Cell and Gene Therapies (CGT), cell therapies, mRNA-based medicines (inc. vaccines), biological samples, and Research and Development (R&D) materials requiring high-integrity cold storage (e.g. plasma, tissue, reagents).

(3) **Cord blood (<-150°C):** Storage of cord blood cell and tissue samples for personal or directed therapeutic use, maintained under validated chain-of-identity controls.

For personal use only

Review of operations

The year ended 30 June 2026 marked a decisive shift in Cryosite's scale and trajectory. The Group delivered record revenue, earnings and operating volumes while managing several complex capital works initiatives including:

- acquisition of a new freehold facility at Adderley Street West, Auburn, NSW (15 minutes' drive from our headquarters), doubling our usable capacity footprint; and
- doubling of our largest walk-in cool room (2°C to 8°C), adding over 100% additional capacity to our most constrained temperature storage asset at our Ferndell Street headquarters.

All reportable segments (Ambient, Cold and Frozen, Ultra-Frozen and Cryogenic, and Cord Blood) recorded both revenue and EBITDA increases against the prior year, with demand strengthening across each of the temperature-controlled categories. Our growth came without compromise to the service we provide clients, with quality metrics through the year the strongest Cryosite has recorded.

Where prior years were defined by building capability, FY26 was defined by converting that capability into capacity expansion. We look forward to our additional capacity being utilised by client-led growth in FY27:

	FY26 ($'000)	% Change	FY25 ($'000)
Revenue	**16,700**	**18%**	**14,116**
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA)	**4,289**	**27%**	**3,367**
EBITDA Margin	26%	2%	24%
Earnings Before Interest and Tax (EBIT)	**3,377**	**35%**	**2,496**
Net Profit After Tax (NPAT)	**2,235**	**19%**	**1,884**
NPAT Margin	13%	0%	13%

The year strengthened as it progressed, producing records across all our key financial metrics.

- **Operational volumes:** increased 17% year-on-year.
- **Quality performance:** Cryosite's team continued to achieve industry-leading quality metrics including our strongest annual performance to date.
- **Cashflow:** The Group ended FY26 with a strong cash balance of $2,244,000 (30 June 2025: $5,060,000), driven by:
  - **Operating Cashflow**: strengthening operational cashflows of $2,820,000 up 37% on FY25 ($2,064,000).
  - **Adderley Street Freehold Facility Acquisition:**
    - a $3,452,000 equity and transaction cost contribution relating to the acquisition of our new freehold facility at 100-104 Adderley Street West, Auburn, NSW
    - $1,000,000 voluntary principal repayment against the debt in April 2026.
  - **Cool Room Expansion:** $390,000 of capital expenditure deployed to increase our primary cool room (2°C to 8°C).

During the period, Cryosite progressed two significant growth initiatives, giving the Group the physical capacity to meet the demand now in front of it:

For personal use only

(1) Acquisition and build-out of new freehold facility (Adderley Street): In October 2025, Cryosite announced the acquisition of our freehold facility at 100-104 Adderley Street West, Auburn, NSW, with settlement in November 2025.

No single investment in the Company's history has been larger. The site is approximately 4km, or a 15-minute drive, from our existing Ferndell Street, South Granville headquarters. This capacity expansion takes the Group's usable storage and warehousing footprint beyond 4,200 sqm, more than double the previous position, and gives clients valuable dual-site resilience.

The strategic rationale was straightforward. Following the 17% mezzanine expansion delivered in the prior year, we could foresee the upcoming constraints on our storage capacity as client demand for regulated temperature-controlled storage continues climbing. At $9.5m, the purchase price was below the $10.5m–$11.3m range implied by comparable sales, and ownership is expected to cost less over time than leasing equivalent space in Western Sydney.

Site readiness works continued through 2HFY26, with the client-led fit-out phase to follow in FY27. Applications to vary our relevant licences have been lodged with the Therapeutic Goods Administration (TGA). In keeping with the Company's capital-efficient approach, the site will be activated in stages matched to client demand, holding operating costs low while the site is scaled up. Once active, Adderley Street opens categories and scaled opportunities previously beyond the Group's reach including medical device and commercial (ARTG) storage, expanded cryogenic storage, bulk and pallet storage, and secondary packaging.

The acquisition was funded through a combination of operating cashflows and a competitively priced debt facility from the National Australia Bank, secured at approximately 70% loan-to-value. In May 2026 the facility was refinanced with NAB on competitive terms for a four-year term maturing in 2030. In line with the repayment strategy outlined to shareholders, approximately $1.0m of principal was repaid during the year, leaving approximately $5.6m outstanding at 30 June 2026. The Group carries no other debt.

Adderley Street Acquisition	$'000
Cash (Equity and transaction costs)	3,452
Debt	6,650
Total acquisition costs	10,102



For personal use only



(2) Expansion of large-scale cool room (Ferndell Street): Work began in December 2025 to extend the primary large-scale cool room (2°C to 8°C) at the Ferndell Street facility. This expansion was only made possible by the operational headroom the Adderley Street acquisition created.

The structural extension was completed during the 2HFY2026 at a capital cost of approximately $0.4m, met entirely from operating cashflows, and more than doubled primary cool room capacity.



Earnings per share

	Cents 2026	Cents 2025
Basic earnings per share	4.58	3.86
Diluted earnings per share	4.34	3.78

For personal use only

Overview

The Directors are pleased to report the financial results for the year ended 30 June 2026 have materially exceeded those of the prior corresponding period. Strong growth was delivered across revenue, operating profit, EBIT and EBITDA, and NPAT margins expanded even after absorbing the interest cost of the Adderley Street NAB facility of approximately $200k.

The Group continues to benefit from a strong economic moat in regulated supply chains, long-duration customer relationships and a global market for specialist temperature-controlled storage and logistics that continues to grow.

The Directors consider Earnings Before Interest and Tax ('EBIT') and Earnings Before Interest, Tax, Depreciation and Amortisation ('EBITDA') to reflect the core earnings of the Group. EBIT and EBITDA are financial measures which are not prescribed by Australian Accounting Standards ('AAS') and represent the profit under AAS adjusted for non-cash and significant items. The Group's reconciliation of its statutory net profit after tax ('NPAT') for the current and previous year to EBIT and EBITDA is as follows:

	2026 $'000	2025 $'000	Change $'000	Change %
Reported financials				
Revenue	16,700	14,116	2,584	18%
Cost of providing services	(6,275)	(5,226)	(1,049)	20%
Gross profit	10,425	8,890	1,535	17%
Net profit after tax	2,235	1,884	351	19%
Add: Income tax expense	919	639	280	44%
Add: Interest expense	336	150	186	124%
Less: Interest revenue calculated using effective interest method	(113)	(177)	64	(36%)
EBIT	3,377	2,496	881	35%
Add: Depreciation and amortisation expense	912	871	41	5%
EBITDA	4,289	3,367	922	27%

Ambient, Cold and Frozen

Revenue in the Group's largest segment rose 22% on record outbound and inbound volumes and steadily rising utilisation of ambient and cool room storage. There were two key drivers for this outcome which included: strengthening activity from new and existing clients and gathering momentum in commercial (ARTG) pharmaceutical handling, which continues to broaden the revenue segment beyond the traditional clinical trial base.

Ultra-Frozen and Cryogenic

Demand for ultra-frozen and cryogenic services rose across existing and new clinical trial sponsors, biotech and R&D clients, reflecting worldwide growth tailwinds in cell and gene therapies, mRNA-based medicines and biological sample storage, fields in which Cryosite's reputation for regulatory compliance and execution capability carries weight. Entry barriers in this segment are significant, client relationships are long-dated and regulatory complexity continues to rise, all of which support revenue growth and client retention.

Cord Blood

The maturing of legacy prepaid contracts, some entered into over terms of 18 to 25 years with cash received upfront, continues to reshape this segment. Renewal rates remain strong, new agreements are largely agreed on an annual basis, and the segment now generates cash of approximately $0.8m per annum, a figure expected to grow as the expiration of further legacy contracts peaks over the next five years. Beyond its financial contribution, Cord Blood represents more than 24 years of cryogenic handling expertise, the foundation on which our Ultra-Frozen and Cryogenic capabilities are built.

People and Capability

Leadership capability deepened during the year. Gavan Corke assumed the General Manager role for the duration of Dr Alicia Steel's parental leave, and Paul Cohen joined to lead the Regulatory Affairs and Quality Assurance function, bringing decades of pharmaceutical and medical device experience.

In February 2026 the Board approved the issue of options under the Cryosite Employee Option Plan (EOP) to tighten the alignment between management incentives and shareholder outcomes. Options issued under the EOP carry vesting conditions designed to reward sustained company performance.

Operational Resilience
Global supply chain and cost pressures required active management through the year. Disruption flowing from conflict in the Middle East was largely absorbed through favourable supplier arrangements, notably fixed fuel surcharge terms that shielded clients from material cost increases when global fuel prices rose sharply.

Investor Engagement
Direct shareholder engagement expanded through the interactive Investor Hub and increased operational updates, including quarterly trading updates. In October 2025, RaaS Advisory published commissioned research recognising Cryosite's leading position in temperature-controlled storage and logistics for the life sciences and pharmaceutical industries. More recently, in June 2026, Curran & Co initiated independent research coverage with a BUY rating.

Outlook

Cryosite enters FY27 with increased capacity, an expanding client base and greater operational resilience. The newly acquired Adderley Street facility, together with the completed cool room expansion, materially expands the Group's operational footprint and strengthens its dual-site resilience and future service capabilities. Early client discussions regarding utilisation of the new premises are progressing well, focused on opportunities in new market segments that further diversify the Group's client base and revenue streams.

The Directors are highly encouraged with the momentum built through FY26, in operational volumes, capacity, earnings and balance sheet strength, which gives the Board confidence that the Group enters FY27 well equipped for further growth.

Dividends
The Board resolved not to declare a dividend for FY26.

Cashflow
Cash on hand at 30 June 2026 was $2,244,000, a decrease of $2,816,000 on FY25 ($5,060,000). The reduction primarily reflects the $3,452,000 contribution to the Adderley Street acquisition and the $1,000,000 voluntary principal repayment, offset by strong operating cashflows of $2,820,000.

A $5,650,000 mortgage facility for the Adderley Street, Auburn warehouse was in place at balance date.

Operating cash flows for the year were $2,820,000 (FY25: $2,064,000), an increase of $757,000, reflecting higher revenues, well managed operating costs and good collection management. Capital expenditure totalled $390,000, primarily relating to the Cool Room expansion project.

Environmental, social and governance (ESG)
The Group is committed to sustainable and responsible business practices. In April 2026, Cryosite was awarded a Gold Medal by EcoVadis for the second consecutive year, recognising its performance across environmental, labour and human rights, ethics and sustainable procurement.

Key ESG initiatives in FY26 included:

For personal use only

For personal use only

- *Environmental:*
  - o Continued investment in energy-efficient infrastructure and GreenPower.
  - o Reported estimated Scope 1 and Scope 2 greenhouse gas emissions of 456 tonnes CO2e for the 2025 calendar year.
  - o Continued refinement of Scope 3 emissions reporting.

- *Social:*
  - o Introduced a paid parental leave policy.
  - o Continued workforce development and workplace health and safety programs.
  - o Commenced development of a Long Service Leave Guideline, scheduled to take effect in FY27.
  - o Commenced planning with an external employment program provider to host workplace placements for people experiencing barriers to workforce participation, with onboarding planned for mid-FY27.
  - o Continued the student placement program with local universities to support early career development and experience.
- *Governance:*
  - o Participated in the EcoVadis assessment process to benchmark performance and identify opportunities for continued improvement across environmental, social and governance practices.

Stability in the state of affairs
Our stability in a changing industry landscape reflects effective strategic planning and execution. It highlights our ability to maintain a steady course while adapting to the evolving needs of our clients and the market.

Governance and Management
The Board upholds the highest standards of corporate governance and ethical behaviour. Enhancements in FY26 included:

- Continued review of governance policies
- Strengthening supplier due diligence and sustainability reporting standards
- Enhancement of internal controls to ensure compliance with regulatory obligations and best-practice corporate governance as the Group scales

Material business risks
The Board actively monitors risks that could impact operations and financial performance. The Group's risk management framework includes robust internal controls, ongoing investment in operational resilience, and regular reviews of emerging threats.

Macroeconomic
Although the Group holds a strong market position, it is not immune to inflationary pressures, supply chain disruptions, and new market entrants.

The Group monitors economic indicators closely and maintains a diversified customer base, including growth in biological storage and cell & gene therapies storage leveraging over 24 years of cryogenic cord blood expertise.

Regulatory compliance
The Group's modern, purpose-built facility is licensed by the Therapeutic Goods Administration (TGA), certified to Good Manufacturing Practice (GMP) standards, and NSW Health for Good Wholesaling Practice of Scheduled medicines.
- Conducts regular audits to ensure compliance with regulatory and customer standards;
- Maintains comprehensive accreditations with management systems that underpin quality assurance; and
- Implements internal controls to ensure adherence to Australian laws and regulations.

Privacy and cybersecurity
Protecting sensitive data remains a top priority:
- The Group has invested in IT infrastructure and staff training; and
- Cybersecurity systems are being aligned with the Australian Signals Directorate (ASD) Essential Eight Maturity Model

For personal use only

Work, health and safety ('WHS')

The Group has a zero-tolerance approach to serious incidents and promotes a strong safety culture through:

- Continuous improvement of WHS practices; and
- Ongoing employee training and engagement in safety programs

Operating risks

- As part of a global clinical trials supply chain, disruptions (such as those experienced during COVID-19) can present challenges and opportunities. Agile operating procedures are in place to respond effectively.
- The Clinical Trials division relies on global pharmaceutical and biotech companies. The Group mitigates concentration risk through client diversification and maintaining high service standards.
- The entry of new competitors or changes in clinical trial delivery models could impact operations. This is mitigated by maintaining licenses and certifications, investing in facilities and services, and strengthening customer relationships and brand reputation both domestically and internationally.

Employees and diversity

As at 30 June 2026, the Group employed 27 full-time equivalent employees (2025: 25 employees), over 60% of whom are Culturally and Linguistically Diverse. We are proud that our staff have a rich mix of backgrounds, experiences and perspectives, giving the Group a unique culture and a competitive advantage.

The Group strives to create an inclusive environment that empowers everyone to contribute and make a real difference. This enables our teams to support the success of our clients, and helps our people reach their full potential.

The Group recognises the value of diversity in the workplace. With over ten different ethnic backgrounds, our staff create a culturally and linguistically diverse workplace. There are numerous religions and cultures. Where possible the Group endeavours to offer flexible work practices. Work life balance is seen as a key retention tool.

The Group is committed to providing equal opportunity for all our staff demonstrated by our overall staff mix of 56% females and 44% males. This is also reflected in the direct reports to the Executive Director with 66% being female. Cryosite is committed to providing a workplace free from any form of harassment, bullying and discrimination.

30 June 2026

	All employees	Management	Team lead	Average age	Board of Directors
Male	12	3	3	25-70	2
Female	15	5	2	25-65	-
Total	27	8	5		2

30 June 2025

	All employees	Management	Team lead	Average age	Board of Directors
Male	11	4	2	31-70	2
Female	14	5	1	24-63	-
Total	25	9	3		2

Significant changes in the state of affairs

The Group completed the acquisition of a freehold warehouse property at 100-104 Adderley Street West, Auburn, NSW, for approximately $10 million. The acquisition provides additional capacity (over 100%), long-term operational flexibility and greater control over infrastructure as Cryosite continues to scale.

There were no other significant changes in the state of affairs of the Group during the financial year.

For personal use only

Matters subsequent to the end of the financial year

No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

Likely developments and expected results of operations

Likely developments in the operations of the Group and the expected results of those operations in subsequent financial years have been discussed where appropriate in the review of operations.

Environmental regulation

The Group provides a range of services that require compliance with legislation and regulations administered by government authorities and statutory bodies, including the Therapeutic Goods Administration (TGA), the Office of Drug Control, the Australian Government Department of Agriculture, Fisheries and Forestry and the New South Wales Department of Health. The Group holds and maintains a Good Manufacturing Practice (GMP) Certification. Additionally, the Group must comply with environmental guidance within the quality system requirements of many of its customers.

Cryosite has a Group-wide quality management system to ensure that it meets or exceeds the requirements of all these interests.

There have been no significant known breaches of Cryosite's license conditions or any regulations to which it is subject. The Group, to the best of its knowledge, is not subject to any specific environmental regulations.

Information on directors

Name:	**Mark Kerr** (appointed on 8 December 2023)
Title:	Non-Executive Chairman
Qualifications:	LLB (The University of Melbourne)
Experience and expertise:	Mark Kerr has a long and successful career with public companies. He is the founding Chairman of Nido Education Ltd, an ASX listed company (ASX: NDO). Mark was also the founding Chairman of Think Childcare Group which was sold to Busy Bees in 2021.
Other current directorships:	Chairman – Nido Education Ltd
Former directorships (last 3 years):	N/A
Special responsibilities:	None
Interests in shares:	9,306,453 ordinary shares
Interests in options:	None

Name:	**Andrew Kerr** (appointed on 22 February 2024)
Title:	Executive Director (Non-Executive Director up to 19 August 2024; appointed as Executive Director on 20 August 2024)
Qualifications:	CPA, GAICD, BCom (The University of Melbourne)
Experience and expertise:	Andrew is an experienced financial services professional in both the Australian and international markets. Andrew has previously worked at Macquarie Bank (Green Investment Group & Commodities and Global Markets divisions), Bank of America Merrill Lynch, and Meridian Energy Australia (Powershop Australia).
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Chair of Audit and Risk Committee; Member of the Remuneration and Nominations Committee
Interests in shares:	None
Interests in options:	1,000,000

Name:	**Scott Thomas** (appointed on 9 May 2024)
Title:	Non-Executive Director
Qualifications:	Diploma of Financial Strategy (Oxford University), Master of Applied Finance (Macquarie University), Bachelor of Commerce (The University of Melbourne)
Experience and expertise:	Scott has strong experience in the financial services profession both in Australia and the United Kingdom having held senior roles at ANZ and Vanguard Investments.
Other current directorships:	None
Former directorships (last 3 years):	None
Special responsibilities:	Chair of the Remuneration and Nominations Committee; Member of Audit and Risk Committee
Interests in shares:	Nil
Interests in options:	None

'Other current directorships' quoted above are current directorships for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

'Former directorships (last 3 years)' quoted above are directorships held in the last 3 years for listed entities only and excludes directorships of all other types of entities, unless otherwise stated.

For personal use only

For personal use only

Company secretary

Hamish George (appointed as Company Secretary on 20 September 2024)
Mr Hamish George is the member of Bio101 Financial Advisory Pty Ltd and remains as Company Secretary.

Hamish is an experienced ASX-listed Company Secretary and is a Director at Bio101 Financial Advisory Pty Ltd, a financial services firm providing outsourced company secretarial, CFO and transactional advisory solutions to the Healthcare sector.

Hamish is a Chartered Accountant and holds a Bachelor of Commerce from the University of Melbourne, a Diploma in Financial Planning from Kaplan Professional, a Master's Degree in Professional Accounting from RMIT and a Certificate in Governance Practice from the Governance Institute of Australia.

Meetings of directors

The number of meetings of the Company's Board of Directors ('the Board') held during the year ended 30 June 2026, and the number of meetings attended by each director were:

	Full Board		Remuneration and Nomination Committee		Audit and Risk Committee	
	Attended	Held	Attended	Held	Attended	Held
Mark Kerr	7	7	-	-	1	1
Andrew Kerr	7	7	1	1	1	1
Scott Thomas	7	7	1	1	1	1

Held: represents the number of meetings held during the time the director held office.

Remuneration report (audited)

The remuneration report details the key management personnel remuneration arrangements for the Group, in accordance with the requirements of the Corporations Act 2001 and its Regulations.

Key management personnel (KMP) are those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including all directors.

The remuneration report is set out under the following main headings:
- Principles used to determine the nature and amount of remuneration
- Details of remuneration
- Service agreements
- Share-based compensation
- Additional information
- Additional disclosures relating to key management personnel

Principles used to determine the nature and amount of remuneration

The Group aims to ensure a competitive level and mix of remuneration to enable the Group to attract, motivate and retain high quality personnel, to help the Group achieve its objectives and advance shareholder returns.

The Board maintains the authority and responsibility for the oversight of the Group's remuneration policy and the principles and processes which underpin the policy. The Board reviews the structure and level of remuneration for the directors and senior executives, and on the design and award of all executive incentive plans.

In accordance with best practice corporate governance, the structure of non-executive director and executive remuneration is separate.

Non-executive directors' remuneration
Fees and payments to non-executive directors reflect the demands and responsibilities of their role and are set to attract a requisite skill set required to govern the Group.

The Group has two non-executive directors as at 30 June 2026. Mark Kerr is deemed not to be independent, due to his substantial shareholding of the Group with a relevant interest at the date of this report of 9,306,453 ordinary shares.

For personal use only

The remuneration of non-executive directors including the Chairman consists of fixed annual fees which are reviewed annually by the Remuneration and Nomination Committee. The Remuneration and Nomination Committee may, from time to time, receive advice from independent remuneration consultants to ensure non-executive directors' fees and payments are appropriate and in line with the market. The Chairman's fees are determined independently to the fees of other non-executive directors based on comparative roles in the external market. The Chairman is not present at any discussions relating to the determination of his own remuneration.

Fixed annual fees for the 2026 year are as follows:
- Non-Executive Chairman: $95,000 maximum per annum, plus superannuation.
- Non-Executive Director: $80,000 maximum per annum, plus superannuation.
- Executive Director: $246,080 maximum per annum, plus superannuation.
- Chair of Remuneration and Nomination Committee: $7,500 maximum per annum, plus superannuation.
- Chair of Audit and Risk Committee: $7,500 maximum per annum, plus superannuation.

The current maximum aggregate remuneration, approved by shareholders, for non-executive directors is $350,000. During 2026 total aggregate remuneration paid to non-executive directors was $189,466 (2025: $185,090).

Apart from reimbursement of expenses incurred on the Group’s behalf, non-executive directors are not eligible for any additional payments. Performance based compensation is not part of the remuneration structure offered to non-executive directors.

Executive remuneration
The Group aims to reward executives based on their position, responsibility, experience and qualifications with a competitive level and mix of remuneration which has both fixed and variable components.

Executive remuneration and reward can consist of the following components:
- fixed remuneration;
- short-term performance incentives, cash-based payments; and
- long-term performance incentives, share-based payments

Fixed remuneration, consisting of base salary, superannuation, non-monetary items and long term benefits, are reviewed annually by the Remuneration and Nomination Committee based on individual and business unit performance, the overall performance of the Group and comparable market remunerations. There is no guaranteed annual increase.

Short-term incentives ('STI') are at-risk cash payments granted to executives based on the achievement of Group wide budgets as well as specific annual targets and key performance indicators ('KPIs') being achieved by the executive. KPIs include profit contribution, customer satisfaction, leadership contribution and product management. All STI payments are approved by the Board, on the recommendation of the Remuneration and Nomination Committee.

Long-term incentives ('LTI') are at risk share-based payments. They provide the opportunity, on invitation, for executives to receive an equity-based payment if the financial performance hurdles associated with each invitation are met. These awards are governed by the Cryosite Employee Option Plan (EOP) approved by the Board of Directors on 27 February 2025, pursuant to clause 74 of the Company Constitution. The Company issued 1 million unlisted options to employees on 17 March 2025, vesting in four tranches expiring 7 years from grant pursuant to EOP. The aim of the EOP is to align executives and senior managers’ long-term variable at risk remuneration with the interests of shareholders. As outlined under clause 5.2 and 5.3 of the Company’s Constitution, the Board has the power to grant options over unissued shares under an EOP.

Performance reviews are conducted annually for all Senior Executives.

Use of remuneration consultants
During the financial year ended 30 June 2026, the Group engaged two remuneration consultants, Thomson Geer ($5,000 paid) and Bio101 ($3,000 paid) to advise on the remuneration package awarded to the directors and KMPs.

For personal use only

An agreed set of protocols were put in place to ensure that the remuneration recommendations would be free from undue influence from key management personnel. These protocols include requiring that the consultant not communicate with affected key management personnel without a member of the Remuneration and Nomination Committee being present, and that the consultant not provide any information relating to the outcome of the engagement with the affected key management personnel. The Board is also required to make inquiries of the consultant's processes at the conclusion of the engagement to ensure that they are satisfied that any recommendations made have been free from undue influence. The Board is satisfied that these protocols were followed and as such there was no undue influence.

Voting and comments made at the Company's 2025 Annual General Meeting ('AGM')
At the 2025 AGM, 99.5% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2025. The Company did not receive any specific feedback at the AGM regarding its remuneration practices.

Details of remuneration

Amounts of remuneration
Details of the remuneration of key management personnel of the Group are set out in the following tables.

The key management personnel of the Group consisted of the following directors of Cryosite Limited:
- Mark Kerr - Non-Executive Chairman
- Andrew Kerr – Executive Director
- Scott Thomas – Non-Executive Director

And the following persons:
- Jane Hao - Chief Financial Officer
- Alicia Steel - General Manager

	Short-term benefits			Post-employment benefits	Long-term benefits	Share-based payments	
2026	Cash salary and fees $	Other Cash benefits $	Non-monetary $	Super-annuation $	Long service leave $	Equity-settled $	Total $
Non-Executive Directors:							
Mark Kerr	88,333	-	-	10,600	-	-	98,933
Scott Thomas	80,833	-	-	9,700	-	-	90,533
Executive Directors:							
Andrew Kerr	229,413	16,667	-	31,147	-	87,315	364,542
Other Key Management Personnel:							
Jane Hao	207,061	10,753	-	39,598	5,816	22,230	285,458
Alicia Steel	190,368	11,162	-	24,058	9,388	65,295	300,271
	796,008	38,582	-	115,103	15,204	174,840	1,139,737

For personal use only

2025	Short-term benefits: Cash salary and fees $	Short-term benefits: Other: Cash benefits $	Short-term benefits: Other: Non-monetary $	Post-employment benefits: Super-annuation $	Long-term benefits: Long service leave $	Share-based payments: Equity-settled $	Total $
Non-Executive Directors:							
Mark Kerr	75,000	-	-	8,625	-	-	83,625
Scott Thomas	68,125	-	-	7,834	-	-	75,959
Executive Directors:							
Andrew Kerr[1]	183,339	50,000	-	21,084	152	-	254,575
Other Key Management Personnel:							
Jane Hao	180,640	10,420	-	44,224	4,869	5,598	245,751
Alicia Steel[2]	181,566	10,816	-	37,671	4,853	15,994	250,900
John Hogg[3]	99,806	-	-	10,227	-	-	110,033
	788,476	71,236	-	129,665	9,874	21,592	1,020,843

(1) Represents remuneration as a Non-Executive Director from 1 July 2024 to 19 August 2024, and as an Executive Director from 20 August 2024 to 30 June 2025.
(2) Represents remuneration from 1 October 2024 to 30 June 2025.
(3) Represents remuneration from 1 July 2024 to 31 October 2024.

The proportion of remuneration linked to performance and the fixed proportion are as follows:

Name	Fixed remuneration 2026	Fixed remuneration 2025	At risk - STI 2026	At risk - STI 2025	At risk - LTI 2026	At risk - LTI 2025
Non-Executive Directors:						
Mark Kerr	100.00%	100.00%	-	-	-	-
Scott Thomas	100.00%	100.00%	-	-	-	-
Executive Directors:						
Andrew Kerr	71.48%	80.36%	4.57%	19.64%	23.95%	-
Other Key Management Personnel:						
Jane Hao	88.44%	93.48%	3.77%	4.24%	7.79%	2.28%
Alicia Steel	74.53%	89.32%	3.72%	4.31%	21.75%	6.37%
John Hogg	-	100.00%	-	-	-	-

Cash bonuses are dependent on meeting defined performance measures. The amount of the bonus is determined having regard to the satisfaction of performance measures as described above in the section in the remuneration report. The maximum bonus values are established at the start of each financial year and amounts payable are determined by the board and paid in the final month of the financial year.

The proportion of the cash bonus paid/payable or forfeited is as follows:

Name	Cash bonus paid/payable 2026	Cash bonus paid/payable 2025	Cash bonus forfeited 2026	Cash bonus forfeited 2025
Other Key Management Personnel:				
Jane Hao	100.00%	100.00%	-	-
Alicia Steel	100.00%	100.00%	-	-
John Hogg	-	100.00%	-	-

For personal use only

Service agreements

Remuneration and other terms of employment for key management personnel are formalised in service agreements. Details of these agreements are as follows:

Name:	Andrew Kerr (appointed Executive on 20 August 2024)
Title:	Executive Director
Agreement commenced:	20 August 2024 (latest agreement date is 1 November 2025)
Term of agreement:	Ongoing (no fixed term)
Details:	Consultancy agreement $246,080 per year plus superannuation. Andrew Kerr or the Group may terminate this agreement by providing the other with six months written notice.
Name:	Jane Hao
Title:	Chief Financial Officer
Agreement commenced:	08 January 2021
Term of agreement:	Permanent
Details:	Base Salary $207,061 plus superannuation. Jane Hao can receive $10,753 bonus annually on her base salary subject to individual and Group performance. Jane Hao or the Group may terminate this agreement by providing the other with three months written notice.
Name:	Alicia Steel
Title:	General Manager
Agreement commenced:	01 October 2024
Term of agreement:	Permanent
Details:	Base Salary $209,553 plus superannuation. Alicia Steel can receive $11,162 bonus annually on her base salary subject to individual and Group performance. Alicia Steel or the Group may terminate this agreement by providing the other with three months written notice.

The Group may terminate the employee's contract without notice if serious misconduct has occurred. Where termination with cause occurs, the executive is only entitled to that portion of remuneration that is fixed, and only up to the date of termination. On termination with cause, any options that have been granted but not vested will be forfeited.

Share-based compensation

Issue of shares

There were no shares issued to directors and other key management personnel as part of compensation during the year ended 30 June 2026.

Options and Performance Rights
The terms and conditions of each grant of options over ordinary shares affecting remuneration of directors and other key management personnel in this financial year or future reporting years are as follows:

Name	Number of options granted	Grant date	Vesting date and exercisable date	Expiry date	Exercise price	Fair value per option at grant date
Alicia Steel	100,000	17/03/2025	1/03/2027	17/03/2032	$0.90	$0.290
Alicia Steel	100,000	17/03/2025	1/03/2028	17/03/2032	$0.90	$0.290
Alicia Steel	75,000	17/03/2025	1/03/2027	17/03/2032	$1.10	$0.250
Alicia Steel	75,000	17/03/2025	1/03/2028	17/03/2032	$1.10	$0.250
Alicia Steel	50,000	17/03/2025	1/03/2027	17/03/2032	$1.20	$0.240
Alicia Steel	50,000	17/03/2025	1/03/2028	17/03/2032	$1.20	$0.240
Alicia Steel	25,000	17/03/2025	1/03/2027	17/03/2032	$1.30	$0.230
Alicia Steel	25,000	17/03/2025	1/03/2028	17/03/2032	$1.30	$0.230
Alicia Steel	46,667	18/03/2026	1/03/2028	26/02/2031	$1.30	$0.380
Alicia Steel	46,667	18/03/2026	1/03/2029	26/02/2031	$1.30	$0.380
Alicia Steel	35,000	18/03/2026	1/03/2028	26/02/2031	$1.50	$0.330
Alicia Steel	35,000	18/03/2026	1/03/2029	26/02/2031	$1.50	$0.330
Alicia Steel	23,333	18/03/2026	1/03/2028	26/02/2031	$1.60	$0.310
Alicia Steel	23,333	18/03/2026	1/03/2029	26/02/2031	$1.60	$0.310
Alicia Steel	11,667	18/03/2026	1/03/2028	26/02/2031	$1.70	$0.290
Alicia Steel	11,667	18/03/2026	1/03/2029	26/02/2031	$1.70	$0.290
Jane Hao	35,000	17/03/2025	1/03/2027	17/03/2032	$0.90	$0.290
Jane Hao	35,000	17/03/2025	1/03/2028	17/03/2032	$0.90	$0.290
Jane Hao	26,250	17/03/2025	1/03/2027	17/03/2032	$1.10	$0.250
Jane Hao	26,250	17/03/2025	1/03/2028	17/03/2032	$1.10	$0.250
Jane Hao	17,500	17/03/2025	1/03/2027	17/03/2032	$1.20	$0.240
Jane Hao	17,500	17/03/2025	1/03/2028	17/03/2032	$1.20	$0.240
Jane Hao	8,750	17/03/2025	1/03/2027	17/03/2032	$1.30	$0.230
Jane Hao	8,750	17/03/2025	1/03/2028	17/03/2032	$1.30	$0.230
Jane Hao	13,333	18/03/2026	1/03/2028	26/02/2031	$1.30	$0.380
Jane Hao	13,333	18/03/2026	1/03/2029	26/02/2031	$1.30	$0.380
Jane Hao	10,000	18/03/2026	1/03/2028	26/02/2031	$1.50	$0.330
Jane Hao	10,000	18/03/2026	1/03/2029	26/02/2031	$1.50	$0.330
Jane Hao	6,667	18/03/2026	1/03/2028	26/02/2031	$1.60	$0.310
Jane Hao	6,667	18/03/2026	1/03/2029	26/02/2031	$1.60	$0.310
Jane Hao	3,333	18/03/2026	1/03/2028	26/02/2031	$1.70	$0.290
Jane Hao	3,333	18/03/2026	1/03/2029	26/02/2031	$1.70	$0.290
Andrew Kerr	200,000	16/10/2025	1/03/2027	16/10/2030	$0.90	$0.250
Andrew Kerr	200,000	16/10/2025	1/03/2028	16/10/2030	$0.90	$0.250
Andrew Kerr	150,000	16/10/2025	1/03/2027	16/10/2030	$1.10	$0.200
Andrew Kerr	150,000	16/10/2025	1/03/2028	16/10/2030	$1.10	$0.200
Andrew Kerr	100,000	16/10/2025	1/03/2027	16/10/2030	$1.20	$0.180
Andrew Kerr	100,000	16/10/2025	1/03/2028	16/10/2030	$1.20	$0.180
Andrew Kerr	50,000	16/10/2025	1/03/2027	16/10/2030	$1.30	$0.160
Andrew Kerr	50,000	16/10/2025	1/03/2028	16/10/2030	$1.30	$0.160

Options granted carry no dividend or voting rights.

For personal use only

For personal use only

The options provide participating employees with the ability to acquire, at a pre-determined fixed prices (i.e. the Exercise Price), a specific number of fully paid ordinary shares in the Company. The options will vest in four Tranches and vesting of options is subject to the satisfaction of the vesting conditions which provided the employee has remained continuously employed by the Company for a period commencing on the issue date up to and including the vesting date. Once the options become Vested Options, the participating employee will be entitled to exercise their Vested Options at any time up until the Expiry Date. If the employee decides not to exercise their options, all of their unexercised options will lapse on the Expiry Date for no monetary consideration (unless otherwise determined by the Board). The options are non-transferable. There are no amounts paid or payable by the option recipient in relation to the granting of such options other than on their potential exercise.

The number of options over ordinary shares granted to and vested by directors and other key management personnel as part of compensation during the year ended 30 June 2026 are set out below:

Name	Number of options granted during the year 2026	Number of options granted during the year 2025	Number of options vested during the year 2026	Number of options vested during the year 2025
Andrew Kerr	1,000,000	-	-	-
Alicia Steel	233,333	500,000	-	-
Jane Hao	66,667	175,000	-	-

Values of options over ordinary shares granted, exercised and lapsed for directors and other key management personnel as part of compensation during the year ended 30 June 2026 are set out below:

Name	Value of options granted during the year $	Value of options exercised during the year $	Value of options lapsed during the year $	Remuneration consisting of options for the year %
Andrew Kerr	215,754	-	-	34%
Alicia Steel	80,131	-	-	20%
Jane Hao	22,895	-	-	7%

Additional information

The earnings of the Group for the five years to 30 June 2026 are summarised below:

	2026 $'000	2025 $'000	2024 $'000	2023 $'000	2022 $'000
Sales revenue	16,700	14,116	12,612	11,935	11,757
EBITDA	4,289	3,367	2,841	2,220	2,445
EBIT	3,377	2,496	2,054	1,524	1,881
Profit after income tax	2,235	1,884	1,840	1,409	1,364

The factors that are considered to affect total shareholders return ('TSR') are summarised below:

	2026	2025	2024	2023	2022
Share price at financial year end ($)	1.25	0.75	1.20	0.63	0.66
Total dividends declared (cents per share)	-	-	2.00	1.50	1.00
Basic earnings per share (cents per share)	4.58	3.86	3.77	2.89	2.79
Diluted earnings per share (cents per share)	4.34	3.78	3.77	2.89	2.79
Share buy-back ($'000)	-	-	2,400	-	-

Additional disclosures relating to key management personnel

Shareholding
The number of shares in the Company held during the financial year by each director and other members of key management personnel of the Group, including their personally related parties, is set out below:

	Balance at the start of the year	Received as part of remuneration	Additions	Disposals/ other	Balance at the end of the year
Ordinary shares					
Mark Kerr	9,231,453	-	75,000	-	9,306,453
	9,231,453	-	75,000	-	9,306,453

Option holding
Options over ordinary shares were issued to other key management personnel as part of compensation as at 30 June 2026.

	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
Options over ordinary shares					
Andrew Kerr	-	1,000,000	-	-	1,000,000
Alicia Steel	500,000	233,333	-	-	733,333
Jane Hao	175,000	66,667	-	-	241,667
	675,000	1,300,000	-	-	1,975,000

Loans to key management personnel and their related parties
There were no loans to key management personnel at the beginning of the year, at any time during the year, or at the end of the year.

Other transactions with key management personnel and their related parties
There were no other transactions with key management personnel and their related parties.

This concludes the remuneration report, which has been audited.

For personal use only

For personal use only

Shares under option

Unissued ordinary shares of Cryosite Limited under option at the date of this report are as follows:

Grant date	Expiry date	Exercise price	Number under option
17/03/2025	17/03/2032	$0.90	200,000
17/03/2025	17/03/2032	$0.90	200,000
17/03/2025	17/03/2032	$1.10	150,000
17/03/2025	17/03/2032	$1.10	150,000
17/03/2025	17/03/2032	$1.20	100,000
17/03/2025	17/03/2032	$1.20	100,000
17/03/2025	17/03/2032	$1.30	50,000
17/03/2025	17/03/2032	$1.30	50,000
16/10/2025	16/10/2030	$0.90	200,000
16/10/2025	16/10/2030	$0.90	200,000
16/10/2025	16/10/2030	$1.10	150,000
16/10/2025	16/10/2030	$1.10	150,000
16/10/2025	16/10/2030	$1.20	100,000
16/10/2025	16/10/2030	$1.20	100,000
16/10/2025	16/10/2030	$1.30	50,000
16/10/2025	16/10/2030	$1.30	50,000
18/03/2026	26/02/2031	$1.30	133,333
18/03/2026	26/02/2031	$1.30	133,333
18/03/2026	26/02/2031	$1.50	100,000
18/03/2026	26/02/2031	$1.50	100,000
18/03/2026	26/02/2031	$1.60	66,667
18/03/2026	26/02/2031	$1.60	66,667
18/03/2026	26/02/2031	$1.70	33,333
18/03/2026	26/02/2031	$1.70	33,333
			2,666,666

No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the Company or of any other body corporate.

Shares under performance rights

There were no unissued ordinary shares of Cryosite Limited under performance rights outstanding at the date of this report.

Shares issued on the exercise of options

There were no ordinary shares of Cryosite Limited issued on the exercise of options during the year ended 30 June 2026 and up to the date of this report.

Indemnity and insurance of officers

The Group holds insurance for all the Directors and Officers against liability, except wilful breach of duty, of a nature that is required to be disclosed under section 300(8) of the Corporations Act 2001. In accordance with commercial practice, further details of the nature of the liabilities insured against and the amount of the premium have not been disclosed.

In addition to the above, the Directors and certain Officers of the Group have entered into a Deed of Indemnity and Access confirming the Group's obligation to maintain an adequate Director and Officer Liability insurance policy and confirming the individual Directors' and Officers' right to access board papers and other Group documents. In return, the individual Directors and Officers have agreed to allow the Group to conduct the defence should the event arise. The Group has not otherwise, during or since the end of the financial year, indemnified or agreed to indemnify an Officer or Auditor of the Group or of any related body corporate against a liability incurred as such an Officer or Auditor.

Indemnity and insurance of auditor

The Group has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Group or any related entity against a liability incurred by the auditor.

During the financial year, the Group has not paid a premium in respect of a contract to insure the auditor of the Group or any related entity.

Proceedings on behalf of the Group

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Group, or to intervene in any proceedings to which the Group is a party for the purpose of taking responsibility on behalf of the Group for all or part of those proceedings.

Non-audit services

There were no non-audit services provided during the financial year by the auditor.

Officers of the Group who are former partners of Forvis Mazars Audit & Assurance Pty Limited

There are no officers of the Group who are former partners of Forvis Mazars Audit & Assurance Pty Limited.

Rounding of amounts

The Group is of a kind referred to in Corporations Instrument 2026/183, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the directors

Mark Kerr

Mark Kerr
Non-Executive Chairman

18 August 2026

For personal use only

5/600 Bourke Street
Melbourne Vic 3000
Australia
Tel +61 3 9252 0800
forvismazars.com/au

For personal use only

Auditor's Independence Declaration
Under Section 307c of the Corporations Act 2001
To the Directors of Cryosite Limited and its Controlled Entities

In relation to our audit of the financial report of Cryosite Limited and its Controlled Entities, I declare that, to the best of my knowledge and belief during the financial year ended 30 June 2026, there have been no contraventions of:

(i) The auditor independence requirements as set out in the Corporations Act 2001 in relation to the audit; and

(ii) Any applicable code of professional conduct in relation to the audit.

Forvis Mazars

Forvis Mazars Audit & Assurance Pty Ltd

Alexis Aupied
Director
Melbourne

18 August 2026

Cryosite Limited
Consolidated statement of profit or loss and other comprehensive income
For the year ended 30 June 2026

	Note	Consolidated 2026 $'000	Consolidated 2025 $'000
Revenue	5	16,700	14,116
Expenses			
Administration expenses	6	(5,386)	(4,771)
Cost of providing services		(6,275)	(5,226)
Depreciation and amortisation expense	6	(912)	(871)
Marketing expenses		(70)	(56)
Occupancy expenses		(897)	(696)
Total expenses		(13,540)	(11,620)
Operating profit		3,160	2,496
Interest revenue calculated using the effective interest method		113	177
Non-operating income		217	-
Finance costs	6	(336)	(150)
Profit before income tax expense		3,154	2,523
Income tax expense	7	(919)	(639)
Profit after income tax expense for the year attributable to the owners of Cryosite Limited		2,235	1,884
		Cents	**Cents**
Basic earnings per share	8	4.58	3.86
Diluted earnings per share	8	4.34	3.78

For personal use only

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Cryosite Limited
Consolidated statement of financial position
As at 30 June 2026

	Note	Consolidated 2026 $'000	Consolidated 2025 $'000
Assets			
Current assets			
Cash and cash equivalents	9	2,244	5,060
Trade and other receivables	10	2,567	2,285
Inventories - stock on hand		57	43
Customer acquisition and fulfilment costs	11	957	1,038
Other assets	12	361	443
Total current assets		6,186	8,869
Non-current assets			
Property, plant and equipment	13	11,853	1,415
Right-of-use assets	14	1,738	1,999
Intangible assets		14	-
Deferred tax assets	7	948	989
Customer acquisition and fulfilment costs	11	5,034	5,992
Other assets	12	198	200
Total non-current assets		19,785	10,595
Total assets		25,971	19,464
Liabilities			
Current liabilities			
Trade and other payables	15	1,722	1,731
Contract liabilities	16	2,011	2,021
Lease liabilities	18	220	199
Provision for income tax	7	288	165
Employee benefits	19	358	349
Other liabilities	21	71	67
Total current liabilities		4,670	4,532
Non-current liabilities			
Trade and other payables	15	442	442
Contract liabilities	16	8,005	9,501
Borrowings	17	5,650	-
Lease liabilities	18	1,848	2,068
Employee benefits	19	141	96
Provisions	20	209	209
Other liabilities	21	156	227
Total non-current liabilities		16,451	12,543
Total liabilities		21,121	17,075
Net assets		4,850	2,389
Equity			
Issued capital	22	3,538	3,538
Reserves	23	258	32
Retained profits/(accumulated losses)		1,054	(1,181)
Total equity		4,850	2,389

The above consolidated statement of financial position should be read in conjunction with the accompanying notes

For personal use only

Cryosite Limited
Consolidated statement of changes in equity
For the year ended 30 June 2026

Consolidated	Issued capital $'000	Reserve $'000	Accumulated losses $'000	Total equity $'000
Balance at 1 July 2024	3,538	-	(2,089)	1,449
Profit after income tax expense for the year	-	-	1,884	1,884
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	1,884	1,884
Transactions with owners in their capacity as owners:				
Share-based payments (note 34)	-	32	-	32
Dividends paid (note 24)	-	-	(976)	(976)
Balance at 30 June 2025	3,538	32	(1,181)	2,389

Consolidated	Issued capital $'000	Reserve $'000	(Accumulated losses) / retained profits $'000	Total equity $'000
Balance at 1 July 2025	3,538	32	(1,181)	2,389
Profit after income tax expense for the year	-	-	2,235	2,235
Other comprehensive income for the year, net of tax	-	-	-	-
Total comprehensive income for the year	-	-	2,235	2,235
Transactions with owners in their capacity as owners:				
Share-based payments (note 34)	-	226	-	226
Balance at 30 June 2026	3,538	258	1,054	4,850

For personal use only

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes

Cryosite Limited
Consolidated statement of cash flows
For the year ended 30 June 2026

	Note	Consolidated 2026 $'000	Consolidated 2025 $'000
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		15,432	12,301
Payments to suppliers and employees (inclusive of GST)		(12,055)	(9,566)
Interest and other finance costs paid		(18)	(21)
Income taxes paid		(631)	(650)
Research and development incentive received		92	-
Net cash from operating activities	33	2,820	2,064
Cash flows from investing activities			
Payments for property, plant and equipment	13	(10,867)	(586)
Interest received		119	166
Net cash used in investing activities		(10,748)	(420)
Cash flows from financing activities			
Proceeds from borrowings		6,650	-
Repayment of borrowings		(1,000)	-
Interest paid on borrowings		(156)	-
Repayment of lease liabilities		(324)	(311)
Interest and other finance costs paid		(55)	-
Dividends paid	24	-	(976)
Net cash from/(used in) financing activities		5,115	(1,287)
Net (decrease)/increase in cash and cash equivalents		(2,813)	357
Cash and cash equivalents at the beginning of the financial year		5,060	4,703
Effects of exchange rate changes on cash and cash equivalents		(3)	-
Cash and cash equivalents at the end of the financial year	9	2,244	5,060

For personal use only

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes

For personal use only

Note 1. General information

The financial statements cover Cryosite Limited as a Group consisting of Cryosite Limited and the entities it controlled at the end of, or during, the year. The financial statements are presented in Australian dollars, which is Cryosite Limited's functional and presentation currency.

Cryosite Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

13a Ferndell Street
South Granville
NSW 2142

A description of the nature of the Group's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 18 August 2026. The directors have the power to amend and reissue the financial statements.

Note 2. Material accounting policies

The accounting policies that are material to the Group are set out either in the respective notes or below. The accounting policies adopted are consistent with those of the previous financial year, unless otherwise stated.

New or amended Accounting Standards and Interpretations adopted

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Group during the financial year ending 30 June 2026.

Accounting standards issued but not yet effective

A number of new accounting standards are effective for annual reporting periods beginning after 1 July 2026 and earlier application is permitted. However, the Group has not early adopted the following new or amended accounting standards in preparing these consolidated financial statements.

A. AASB 18 Presentation and Disclosure in Financial Statements
AASB 18 will replace AASB 101 Presentation of Financial Statements and applies for annual reporting periods beginning on or after 1 January 2027. The new standard introduces the following key new requirements.

- Entities are required to classify all income and expenses into five categories in the statement of profit or loss, namely the operating, investing, financing, discontinued operations and income tax categories. Entities are also required to present a newly-defined operating profit subtotal. Entities' net profit will not change.
- Management-defined performance measures (MPMs) are disclosed in a single note in the financial statements.
- Enhanced guidance is provided on how to group information in the financial statements.

In addition, all entities are required to use the operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method.

The Group is still in the process of assessing the impact of the new standard, particularly with respect to the structure of the Group's statement of profit or loss, the statement of cash flows and the additional disclosures required for MPMs. The Group is also assessing the impact on how information is grouped in the financial statements, including for items currently labelled as 'other'.

B. Other accounting standards
The following new and amended accounting standards are not expected to have a significant impact on the Group's consolidated financial statements.

For personal use only

Note 2. Material accounting policies (continued)

- Classification and Measurement of Financial Instruments (AASB 2024-2: Amendments to AASB 9 and AASB 7, effective for 30 June 2027 year-end)

Basis of preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the Corporations Act 2001, as appropriate for for-profit oriented entities. These financial statements also comply with IFRS Accounting Standards as issued by the International Accounting Standards Board ('IASB').

Historical cost convention
The financial statements have been prepared under the historical cost convention.

Critical accounting estimates
The preparation of the financial statements requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the financial statements, are disclosed in note 3.

Parent entity information

In accordance with the Corporations Act 2001, these financial statements present the results of the Group only. Supplementary information about the parent entity is disclosed in note 31.

Principles of consolidation

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of Cryosite Limited ('Company' or 'parent entity') as at 30 June 2026 and the results of all subsidiaries for the year then ended. Cryosite Limited and its subsidiaries together are referred to in these financial statements as the 'Group'.

Subsidiaries are all those entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases.

Intercompany transactions, balances and unrealised gains on transactions between entities in the Group are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

The acquisition of subsidiaries is accounted for using the acquisition method of accounting. A change in ownership interest, without the loss of control, is accounted for as an equity transaction, where the difference between the consideration transferred and the book value of the share of the non-controlling interest acquired is recognised directly in equity attributable to the parent.

Where the Group loses control over a subsidiary, it derecognises the assets including goodwill, liabilities and non-controlling interest in the subsidiary together with any cumulative translation differences recognised in equity. The Group recognises the fair value of the consideration received and the fair value of any investment retained together with any gain or loss in profit or loss.

Finance costs

Finance costs attributable to qualifying assets are capitalised as part of the asset. All other finance costs are expensed in the period in which they are incurred.

Rounding of amounts

The Company is of a kind referred to in Corporations Instrument 2026/183, issued by the Australian Securities and Investments Commission, relating to 'rounding-off'. Amounts in this report have been rounded off in accordance with that Corporations Instrument to the nearest thousand dollars, or in certain cases, the nearest dollar.

For personal use only

Note 3. Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

Determining the timing of satisfaction of performance obligations
The Group concluded that a portion of the revenue from collection, processing and storage of cord blood and tissue should be recognised over time because the customer simultaneously receives and consumes the benefits provided by the Group. The Group determined that the contract term of multi-year contracts, (historically as long as 18 or 25 years in duration) is the best method to determine the timing of satisfaction of performance obligations.

Allowance for expected credit losses
The measurement of expected credit losses is a function of the probability of default, loss given default (i.e., the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data adjusted by forward-looking information. The allowance for expected credit losses, as disclosed in note 10, is calculated based on the information available at the time of preparation.

As for the exposure at default, for financial assets, this is represented by the assets' gross carrying amount at the reporting date. The expected credit loss is estimated as the difference between all contractual cash flows that are due to the Group in accordance with the contract and all the cash flows that the Group expects to receive, discounted at the original effective interest rate.

Consideration of significant financing component in a contract
Historically, the storage contract for cord blood and cord tissue was either 18 or 25 years and the payment options available to the customers were:

- Upfront payment of the full contract price at inception of the contract;
- Instalment payment of either 12 or 24 months; and
- Partial upfront settlement with the remaining balance paid in instalment throughout the life of the contract (referred to by the Group as “Annual plans”).

Management determined that there is a significant financing component included in these 'Annual plans' because the total amount paid under this plan is significantly higher than the upfront cash payment. The amount of financing component attributed to the contract is determined as the difference between the total 'Annual plan' payments and the upfront cash payment.

Income tax
Uncertainties exist with respect to the interpretation of complex tax regulations, changes in tax laws and the amount and timing of future taxable income. The Group’s accounting policy for taxation requires management’s judgement as to the types of arrangements considered to be a tax on income in contrast to an operating cost. Judgement is also required in assessing whether deferred tax assets and certain deferred tax liabilities are recognised in the statement of financial position. Deferred tax assets, including those arising from carry forward tax losses, capital losses and temporary differences, are recognised only where it is considered more likely than not that they will be recovered, which is dependent on the generation of sufficient future taxable profits.

Note 4. Operating segments

Identification of reportable operating segments
In FY25, the Group experienced material growth in Ultra-Frozen and Cryogenic revenues. As a result, the Directors have elected to separate the former ***clinical trials and biological services logistics*** segment into two new streams based on their controlled-temperature ranges: ***ambient, cold, and frozen, and ultra-frozen and cryogenic***. There were no changes to the cord blood reporting segment.

These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources. There is no aggregation of operating segments.

Ambient, cold, and frozen	Storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions. This includes Good Manufacturing Practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements.
Ultra-frozen and cryogenic	Specialised handling of materials requiring Ultra-Frozen or Cryogenic conditions, including Advanced Therapy Medicinal Products (ATMPs), such as Cell and Gene Therapies (CGT), cell therapies, mRNA-based medicines (inc. vaccines), biological samples, and Research and Development (R&D) materials requiring high-integrity cold storage (e.g. plasma, tissue, reagents).
Cord blood	Storage of cord blood cell and tissue samples for personal or directed therapeutic use, maintained under validated chain-of-identity controls.

The CODM review EBITDA (earnings before interest, tax, depreciation and amortisation). The accounting policies adopted for internal reporting to the CODM are consistent with those adopted in the financial statements.

The information reported to the CODM is on a monthly basis.

Major customers
The Group services a highly specialised and often concentrated market segment, of which during the year ended 30 June 2026, approximately 67% (30 June 2025: 78%) of the Group's external revenue was derived from sales to three major global clients.

For personal use only

Note 4. Operating segments (continued)

Operating segment information

Consolidated - 2026	Ambient, cold, and frozen $'000	Ultra-frozen and cryogenic $'000	Cord blood $'000	Corporate $'000	Total $'000
Revenue					
Sales to external customers	12,017	2,276	2,407	-	16,700
Total revenue	12,017	2,276	2,407	-	16,700
EBITDA	4,885	930	828	(2,354)	4,289
Depreciation and amortisation expense	(433)	(164)	(21)	(294)	(912)
Interest revenue	-	-	-	113	113
Finance costs	(34)	(8)	(25)	(269)	(336)
Profit/(loss) before income tax expense	4,418	758	782	(2,804)	3,154
Income tax expense					(919)
Profit after income tax expense					2,235
Assets					
Segment assets	3,629	554	6,815	14,973	25,971
Total assets					25,971
Liabilities					
Segment liabilities	1,232	94	10,382	9,413	21,121
Total liabilities					21,121

Consolidated - 2025	Ambient, cold, and frozen $'000	Ultra-frozen and cryogenic $'000	Cord blood $'000	Corporate $'000	Total $'000
Revenue					
Sales to external customers	9,888	1,857	2,371	-	14,116
Total revenue	9,888	1,857	2,371	-	14,116
EBITDA	4,266	817	722	(2,438)	3,367
Depreciation and amortisation expense	(430)	(73)	(6)	(362)	(871)
Interest revenue	-	-	-	177	177
Finance costs	(86)	(22)	(11)	(31)	(150)
Profit/(loss) before income tax expense	3,750	722	705	(2,654)	2,523
Income tax expense					(639)
Profit after income tax expense					1,884
Assets					
Segment assets	2,937	708	7,969	7,850	19,464
Total assets					19,464
Liabilities					
Segment liabilities	1,267	81	11,932	3,795	17,075
Total liabilities					17,075

Geographical information
The sales to external customers for all three operating segments are from Australia.

For personal use only

For personal use only

Note 5. Revenue

	Consolidated 2026 $'000	Consolidated 2025 $'000
Revenue from contracts with customers		
Revenue from ambient, cold, and frozen	12,017	9,888
Revenue from ultra-frozen and cryogenic	2,276	1,857
Revenue from cord blood (i)	2,407	2,371
Revenue	16,700	14,116

	Consolidated 2026 $'000	Consolidated 2025 $'000
(i) Cord blood comprised of:		
Cord blood revenue	776	580
Cord blood historical contract revenue	1,631	1,791
Total cord blood revenue	2,407	2,371

	Consolidated 2026	Consolidated 2025
** Cord blood deferred revenues and costs are comprised of:*		
Cord blood historical contract liabilities	1,631	1,791
Cord blood historical contract assets	(1,039)	(1,126)
Cord blood historical deferred income tax expense	(148)	(166)
Total cord blood historical deferred net income	444	499

* Refer to note 4 'Operating segments'.

Disaggregation of revenue
The disaggregation of revenue from contracts with customers is as follows:

	Consolidated 2026 $'000	Consolidated 2025 $'000
Geographical regions		
Australia*	16,700	14,116
Timing of revenue recognition		
Goods transferred at a point in time	2,807	2,377
Services transferred over time	13,893	11,739
	16,700	14,116

* The geographical regions are determined based on the place where the services occur.

Accounting policy for revenue recognition
The Group recognises revenue as follows:

Sale of goods
Revenue from the sale of goods is recognised at the point in time when the customer obtains control of the goods, which is generally at the time of delivery.

For personal use only

Note 5. Revenue (continued)

Rendering of services
The Group provides the following services:

- specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, and reverse logistics.
- specialist management of advanced therapies, including Cell and Gene Therapies (CGT), CAR-T therapies, mRNA-based products, biological samples, and R&D materials etc that requires ultra-frozen to cryogenic conditions.
- long term storage for cord blood and tissue samples.

Revenue from ambient, cold, frozen and ultra-frozen and cryogenic
Revenue from Ambient, Cold, and Frozen pertain to processing and distribution of samples for temperature-controlled logistics and depot services. The Group has assessed that each sample processed is distinct from each other and that asset is transferred to the customer over time.

Revenue from Ultra-Frozen and Cryogenic
Revenue from Ultra-Frozen and Cryogenic pertain to processing and distribution of samples under ultra-frozen to cryogenic conditions. The Group has assessed that each sample processed is distinct from each other and that asset is transferred to the customer over time.

Revenue from cord blood
The collection, processing and storage services for cord blood and tissue samples constitute a single performance obligation because none of the services are distinct and marketed independently of the others Therefore, this single performance obligation is performed over time (i.e., throughout the storage contract period of 18 or 25 years). Deferred revenue and deferred costs are consequently recognised in the statement of financial position, and these are unwound to the statement of profit or loss for the remaining contract period. The Company ceased collection and storage of new cord blood/tissue samples in 2017, but continues offering ongoing storage services for existing clients.

Note 6. Expenses

	Consolidated 2026 $'000	Consolidated 2025 $'000
Profit before income tax includes the following specific expenses:		
Depreciation and amortisation expense		
Depreciation - Property plant and equipment	425	575
Depreciation - Right-of-use assets	261	260
Amortisation - Employee options	226	32
Amortisation - Intangibles assets	-	4
Total depreciation and amortisation	912	871
Finance costs		
Interest portion of monies owed to ACCC	16	20
Interest and finance charges paid/payable on lease liabilities	120	130
Interest on the NAB Loan	200	-
Finance costs expensed	336	150
Superannuation expense		
Defined contribution superannuation expense	397	348
Employee benefits expense excluding superannuation		
Employee benefits expense excluding superannuation	3,204	2,775

For personal use only

Note 7. Income tax

	Consolidated 2026 $'000	Consolidated 2025 $'000
Income tax expense		
Current tax	754	598
Deferred tax - origination and reversal of temporary differences	41	41
Adjustment recognised for prior periods	124	-
Aggregate income tax expense	919	639
Deferred tax included in income tax expense comprises:		
Decrease in deferred tax assets	41	41
Numerical reconciliation of income tax expense and tax at the statutory rate		
Profit before income tax expense	3,154	2,523
Tax at the statutory tax rate of 25%	789	631
Adjustment recognised for prior periods	124	-
Other item	-	8
Tax expense - permanent differences	6	-
Income tax expense	919	639

The income tax expense is recognised based on the best estimate of the weighted average annual income tax rate. The estimate takes into account the unutilised tax losses and anticipated tax payable.

	Consolidated 2026 $'000	Consolidated 2025 $'000
Deferred tax asset		
Deferred tax asset comprises temporary differences attributable to:		
Amounts recognised in profit or loss:		
Historical deferred revenue cord blood*	2,226	2,634
Historical deferred cost cord blood**	(1,498)	(1,758)
Other items	220	113
Deferred tax asset	948	989
Movements:		
Opening balance	989	1,030
Charged to profit or loss	(41)	(41)
Closing balance	948	989

	Consolidated 2026 $'000	Consolidated 2025 $'000
Provision for income tax		
Provision for income tax	288	165

Note 7. Income tax (continued)

	Consolidated 2026 $'000	Consolidated 2025 $'000
**Historical deferred revenue cord blood*		
Opening balance	2,634	3,081
Movement	(408)	(447)
Closing balance	2,226	2,634
***Historical deferred cost cord blood*		
Opening balance	(1,758)	(2,039)
Movement	260	281
Closing balance	(1,498)	(1,758)
Deferred tax asset (net)	728	876

Accounting policy for income tax
The income tax expense or benefit for the period is the tax payable on that period's taxable income based on the applicable income tax rate for each jurisdiction, adjusted by the changes in deferred tax assets and liabilities attributable to temporary differences, unused tax losses and the adjustment recognised for prior periods, where applicable.

Deferred tax assets and liabilities are recognised for temporary differences at the tax rates expected to be applied when the assets are recovered or liabilities are settled, based on those tax rates that are enacted or substantively enacted, except for:

- when the deferred income tax asset or liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and that, at the time of the transaction, affects neither the accounting nor taxable profits; or
- when the taxable temporary difference is associated with interests in subsidiaries, associates or joint ventures, and the timing of the reversal can be controlled and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred tax assets are recognised for deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

The carrying amount of recognised and unrecognised deferred tax assets are reviewed at each reporting date. Deferred tax assets recognised are reduced to the extent that it is no longer probable that future taxable profits will be available for the carrying amount to be recovered. Previously unrecognised deferred tax assets are recognised to the extent that it is probable that there are future taxable profits available to recover the asset.

Deferred tax assets and liabilities are offset only where there is a legally enforceable right to offset current tax assets against current tax liabilities and deferred tax assets against deferred tax liabilities; and they relate to the same taxable authority on either the same taxable entity or different taxable entities which intend to settle simultaneously.

Cryosite Limited (the 'head entity') and its wholly-owned Australian subsidiaries have formed an income tax consolidated group under the tax consolidation regime. The head entity and each subsidiary in the tax consolidated group continue to account for their own current and deferred tax amounts. The tax consolidated group has applied the 'separate taxpayer within group' approach in determining the appropriate amount of taxes to allocate to members of the tax consolidated group.

In addition to its own current and deferred tax amounts, the head entity also recognises the current tax liabilities (or assets) and the deferred tax assets arising from unused tax losses and unused tax credits assumed from each subsidiary in the tax consolidated group.

For personal use only

For personal use only

Note 7. Income tax (continued)

Assets or liabilities arising under tax funding agreements with the tax consolidated entities are recognised as amounts receivable from or payable to other entities in the tax consolidated group. The tax funding arrangement ensures that the intercompany charge equals the current tax liability or benefit of each tax consolidated group member, resulting in neither a contribution by the head entity to the subsidiaries nor a distribution by the subsidiaries to the head entity.

An income tax benefit will arise for the financial year where an income tax loss is incurred and, where permitted to do so, is carried-back against a qualifying prior period's tax payable to generate a refundable tax offset.

Note 8. Earnings per share

	Consolidated 2026 $'000	Consolidated 2025 $'000
Profit after income tax attributable to the owners of Cryosite Limited	2,235	1,884
	Number	**Number**
Weighted average number of ordinary shares used in calculating basic earnings per share	48,809,563	48,809,563
Adjustments for calculation of diluted earnings per share:		
Options over ordinary shares	2,666,667	1,000,000
Weighted average number of ordinary shares used in calculating diluted earnings per share	51,476,230	49,809,563
	Cents	**Cents**
Basic earnings per share	4.58	3.86
Diluted earnings per share	4.34	3.78

There have been no other transactions involving ordinary shares or potential ordinary shares since the reporting date and before completion of these financial statements.

Accounting policy for earnings per share

Basic earnings per share
Basic earnings per share is calculated by dividing the profit attributable to the owners of Cryosite Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year.

Diluted earnings per share
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

For personal use only

Note 9. Cash and cash equivalents

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current assets		
Cash at bank and on hand	744	1,060
Short-term deposits	1,500	4,000
	2,244	5,060

Cash at bank and on hand earns interest at floating rates based on daily bank deposit rates. Short-term deposits are made for varying periods of between one day and six months depending on the immediate cash requirements of the Group and earn interest at the respective short-term deposit rates.

Note 10. Trade and other receivables

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current assets		
Trade receivables	2,569	2,148
Accrued receivables	67	171
Less: Allowance for expected credit losses	(116)	(93)
	2,520	2,226
Other receivables	47	59
	2,567	2,285

Allowance for expected credit losses
The Group has recognised a loss of $85,000 (2025: recovery of $14,000) in profit or loss in respect of the expected credit losses for the year ended 30 June 2026.

The ageing of the receivables and allowance for expected credit losses provided for above are as follows:

	Expected credit loss rate		Carrying amount		Allowance for expected credit losses	
Consolidated	2026 %	2025 %	2026 $'000	2025 $'000	2026 $'000	2025 $'000
Not overdue	0.7%	1.8%	2,417	1,914	16	34
0 to 30 days overdue	12.9%	8.9%	113	156	15	14
31 to 60 days overdue	27.5%	17.3%	18	62	5	11
61 to 90 days overdue	30.7%	30.4%	11	21	3	6
91 to 120 days overdue	100.0%	100.0%	22	5	22	5
121 days and above overdue	100.0%	14.1%	55	161	55	23
			2,636	2,319	116	93

Note 10. Trade and other receivables (continued)

Movements in the allowance for expected credit losses are as follows:

	Consolidated 2026 $'000	2025 $'000
Opening balance	93	110
Unused amounts reversed	(62)	(3)
Additional provisions recognised	85	(14)
Closing balance	116	93

Accounting policy for trade and other receivables
Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Trade receivables are generally due for settlement within 30 days.

The Group has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue. Based on historical credit losses, the Group determined the presumption that default occurs later than when a trade receivable is 91 days past due.

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

Note 11. Customer acquisition and fulfilment costs

	Consolidated 2026 $'000	2025 $'000
Current assets		
Deferred costs - cord blood	957	1,038
Non-current assets		
Deferred costs - cord blood	5,034	5,992
	5,991	7,030
Reconciliation of historical deferred cost cord blood		
Opening balance	7,030	8,156
Recognised in the current year	(1,039)	(1,126)
Closing balance	5,991	7,030

Deferred costs represent upfront costs, such as laboratory fees, attributable for the collection and processing of cord blood and tissue samples.

Accounting policy for Customer acquisition and fulfilment costs assets
Costs to fulfil a contract are recognised as a contract asset if costs relate directly to a contract, generate or enhance resources that will be used in satisfying performance obligations and are expected to be recovered. The capitalised contract assets are amortised over a period on a systematic basis that is consistent with the Group's transfer of the related goods or services to the customer.

For personal use only

For personal use only

Note 12. Other assets

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current assets		
Prepayments	361	443
Non-current assets		
Security deposits	198	198
Other non-current assets	-	2
	198	200
	559	643

Note 13. Property, plant and equipment

	Consolidated 2026 $'000	Consolidated 2025 $'000
Non-current assets		
Land, building and capital works - at cost	10,108	-
Less: Accumulated depreciation	-	-
	10,108	-
Leasehold improvements - at cost	149	149
Less: Accumulated depreciation	(139)	(125)
	10	24
Fixtures and fittings - at cost	156	156
Less: Accumulated depreciation	(139)	(131)
	17	25
Information technology - at cost	348	276
Less: Accumulated depreciation	(276)	(244)
	72	32
Office furniture and equipment - at cost	76	68
Less: Accumulated depreciation	(48)	(45)
	28	23
Warehouse equipment - at cost	5,310	4,911
Less: Accumulated depreciation	(3,960)	(3,600)
	1,350	1,311
Tangible assets under construction - at cost	268	-
	11,853	1,415

Note 13. Property, plant and equipment (continued)

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Land, building and capital works	Leasehold improvements	Fixtures and fittings	Information technology	Office furniture and equipment	Warehouse equipment	Tangible assets under construction - at cost	Total
	$'000	$'000	$'000	$'000	$'000	$'000	$'000	$'000
Balance at 1 July 2024	-	52	33	61	35	1,074	196	1,451
Additions	-	-	-	16	-	523	-	539
Transfer	-	-	-	-	-	196	(196)	-
Depreciation expense	-	(28)	(8)	(45)	(12)	(482)	-	(575)
Balance at 30 June 2025	-	24	25	32	23	1,311	-	1,415
Additions	10,108	-	-	72	21	398	268	10,867
Disposals	-	-	-	-	(4)	-	-	(4)
Depreciation expense	-	(14)	(8)	(32)	(12)	(359)	-	(425)
Balance at 30 June 2026	10,108	10	17	72	28	1,350	268	11,853

During the reporting period, the Group completed the acquisition of a new warehouse property at 100–104 Adderley Street West, Auburn, NSW for a total consideration of $10.1 million, inclusive of land, building and directly attributable acquisition costs.

The acquisition was funded through a combination of:
- $3.45 million from existing cash reserves; and
- A new $6.65 million secured interest-only bank loan facility. Refer to note 17.

Accounting policy for property, plant and equipment
Each item of property, plant and equipment (excluding land) is depreciated over their expected useful lives as follows:

Building and capital works	25-40 years
Leasehold improvements	5 years
Fixtures and fittings	5-10 years
Information technology	2.5-5 years
Office furniture and equipment	2.5-8 years
Warehouse equipment	4-10 years

Leasehold improvements are depreciated over the unexpired period of the lease or the estimated useful life of the assets, whichever is shorter.

For personal use only

Note 14. Right-of-use assets

	Consolidated 2026 $'000	Consolidated 2025 $'000
Non-current assets		
Land and buildings - right-of-use	3,430	3,430
Less: Accumulated depreciation	(1,692)	(1,431)
	1,738	1,999

The Group leases land and buildings for its offices and warehouses under an agreement for 5 years to 30 June 2028, with the option to extend the lease by 5 years to 30 June 2033. The lease calculation has been prepared on the basis that the extension option will be exercised.

For other AASB 16 lease related disclosures refer to the following:
- note 6 for details of interest on lease liabilities and other lease payments;
- note 25 for lease liabilities at the end of the reporting period;
- note 25 for undiscounted future lease commitments; and
- consolidated statement of cash flows for repayment of lease liabilities.

Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:

Consolidated	Land and buildings $'000
Balance at 1 July 2024	2,259
Depreciation expense	(260)
Balance at 30 June 2025	1,999
Depreciation expense	(261)
Balance at 30 June 2026	1,738

Accounting policy for right-of-use assets
Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of-use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

For personal use only

For personal use only

Note 15. Trade and other payables

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current liabilities		
Trade payables	888	1,070
Other payables	834	661
	1,722	1,731
Non-current liabilities		
Client deposits	442	442
	2,164	2,173

Refer to note 25 for further information on financial instruments.

Accounting policy for trade and other payables
Trade and other payables represent liabilities for goods and services provided to the Group prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

Note 16. Contract liabilities

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current liabilities		
Contract liabilities	2,011	2,021
Non-current liabilities		
Contract liabilities	8,005	9,501
	10,016	11,522

Reconciliation
Reconciliation of the written down values at the beginning and end of the current and previous financial year are set out below:

Opening balance	11,522	13,021
Payments received in advance	970	987
Transfer to revenue - included in the opening balance	(2,018)	(2,096)
Transfer to revenue - other balances	(458)	(390)
Closing balance	10,016	11,522

Unsatisfied performance obligations
The aggregate amount of the transaction price allocated to the performance obligations that are unsatisfied at the end of the reporting period was $10,016,000 as at 30 June 2026 ($11,522,000 as at 30 June 2025) and is expected to be recognised as revenue in future periods as follows:

Note 16. Contract liabilities (continued)

	Consolidated 2026 $'000	Consolidated 2025 $'000
Within 1 year	2,011	2,021
2 to 3 years	2,678	2,968
4 to 5 years	1,957	2,374
over 5 years	3,370	4,159
	10,016	11,522

Accounting policy for contract liabilities
Contract liabilities represent the Group's obligation to transfer goods or services to a customer and are recognised when a customer pays consideration, or when the Group recognises a receivable to reflect its unconditional right to consideration (whichever is earlier) before the Group has transferred the goods or services to the customer.

Note 17. Borrowings

	Consolidated 2026 $'000	Consolidated 2025 $'000
Non-current liabilities		
Bank loan - secured	5,650	-

Refer to note 25 for further information on financial instruments.

During the year, the Group entered a new bank facility. The borrowing is measured at amortised cost in accordance with AASB 9.

On 14 October 2025, the Group entered into a Business Letter of Offer with National Australia Bank Limited (NAB) for a NAB Corporate Markets Loan facility with a total limit of $6,650,000. The facility is intended to fund the purchase of non-residential industrial property.

The loan facility was secured at approximately 70% loan-to-value, settled on 26 Nov 2025. The loan is interest-only, with the principal repayable in full on the final repayment date.

Interest is charged at a floating rate, being the Bank Bill Swap Reference Rate (BBSY) plus applicable margins, with interest repriced every three months. A facility fee of 1.40% per annum is payable on the approved facility limit.

In May 2026 the facility was refinanced with NAB on competitive terms for a four-year term maturing in 2030. In line with the repayment strategy outlined to shareholders, approximately $1.0m of principal was repaid during the year, leaving approximately $5.6m outstanding at 30 June 2026.

Assets pledged as security
- A General Security Agreement over all present and future assets of the Group;
- a registered mortgage over the property located at 100–104 Adderley Street West, Auburn, NSW; and
- a Guarantee and Indemnity provided by the Group, supported by a general security agreement over all of its assets.

The bank loan is subject to certain financial covenants. The loan will be repayable immediately if the covenants are breached. The Group is not aware of any facts or circumstances that indicate that it may have difficulty complying with the covenants within 12 months after the reporting period.

For personal use only

Note 17. Borrowings (continued)

Financing arrangements
Unrestricted access was available at the reporting date to the following lines of credit:

	Consolidated 2026 $'000	Consolidated 2025 $'000
Total facilities		
Bank loans	5,650	-
Used at the reporting date		
Bank loans	5,650	-
Unused at the reporting date		
Bank loans	-	-

Accounting policy for borrowings
Loans and borrowings are initially recognised at the fair value of the consideration received, net of transaction costs. They are subsequently measured at amortised cost using the effective interest method.

Note 18. Lease liabilities

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current liabilities		
Lease liability	220	199
Non-current liabilities		
Lease liability	1,848	2,068
	2,068	2,267

Refer to note 25 for further information on financial instruments.

Accounting policy for lease liabilities
A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Group's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

For personal use only

Note 19. Employee benefits

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current liabilities		
Annual leave	229	195
Long service leave	129	154
	358	349
Non-current liabilities		
Long service leave	141	96
	499	445

Amounts not expected to be settled within the next 12 months
The current provision for employee benefits includes all unconditional entitlements where employees have completed the required period of service and also those where employees are entitled to pro-rata payments in certain circumstances. The entire amount is presented as current, since the Group does not have an unconditional right to defer settlement. However, based on past experience, the Group does not expect all employees to take the full amount of accrued leave or require payment within the next 12 months.

The following amounts reflect leave that is not expected to be taken within the next 12 months:

	Consolidated 2026 $'000	Consolidated 2025 $'000
Employee benefits obligation expected to be settled after 12 months	141	96

Accounting policy for employee benefits

Short-term employee benefits
Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled wholly within 12 months of the reporting date are measured at the amounts expected to be paid when the liabilities are settled.

Other long-term employee benefits
The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are measured at the present value of expected future payments to be made in respect of services provided by employees up to the reporting date. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on high quality corporate bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Defined contribution superannuation expense
Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

For personal use only

For personal use only

Note 20. Provisions

	Consolidated 2026 $'000	Consolidated 2025 $'000
Non-current liabilities		
Lease make good	209	209

Lease make good
The provision represents the present value of the estimated costs to make good the premises leased by the Group at the end of the respective lease terms.

On 1 July 2023 the current lease agreement with Allsup Pty Limited for the premises in Granville, was extended until 30 June 2028, with option to extend to 30 June 2033. The lease make good provision was increased by $9,000 to $209,000 in respect of the Group's obligation to reflect this arrangement regarding the leased premises. Because of the long-term nature of the liability, there is uncertainty in estimating the actual cost that may ultimately be incurred and any impacts on this of renegotiated terms at the time of lease expiry.

Accounting policy for provisions
Provisions are recognised when the Group has a present (legal or constructive) obligation as a result of a past event, it is probable the Group will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. If the time value of money is material, provisions are discounted using a current pre-tax rate specific to the liability. The increase in the provision resulting from the passage of time is recognised as a finance cost.

Note 21. Other liabilities

	Consolidated 2026 $'000	Consolidated 2025 $'000
Current liabilities		
Other liabilities	71	67
Non-current liabilities		
Other liabilities	156	227
	227	294

As at 30 June 2026, an amount of $227,000 (2025: $294,000) remains payable to the Australian Competition and Consumer Commission ('ACCC') under the deferred settlement arrangement that commenced in 2019. An amount of $85,000 is payable per year, with the final payment due in 2029.

Note 22. Issued capital

	Consolidated 2026 Shares	Consolidated 2025 Shares	Consolidated 2026 $'000	Consolidated 2025 $'000
Ordinary shares - fully paid	48,809,563	48,809,563	3,538	3,538

Ordinary shares
Ordinary shares entitle the holder to participate in any dividends declared and any proceeds attributable to shareholders should the Company be wound up, in proportions that consider both the number of shares held and the extent to which those shares are paid up. The fully paid ordinary shares have no par value and the Company does not have a limited amount of authorised capital.

Note 22. Issued capital (continued)

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back
There is no current on-market share buy-back.

Capital risk management
The Group's objectives when managing capital is to safeguard its ability to continue as a going concern, so that it can provide returns for shareholders and benefits for other stakeholders and to maintain an optimum capital structure to reduce the cost of capital.

Capital is regarded as total equity, as recognised in the statement of financial position, plus net debt. Net debt is calculated as total borrowings less cash and cash equivalents.

In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

The Group would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current Company's share price at the time of the investment.

The Group's approach to capital risk management remains unchanged from the 30 June 2025 Annual report.

Accounting policy for issued capital
Ordinary shares are classified as equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

Note 23. Reserves

	Consolidated 2026 $'000	Consolidated 2025 $'000
Share-based payments reserve	258	32

Share-based payments reserve
The reserve is used to recognise the value of equity benefits provided to employees and directors as part of their remuneration, and other parties as part of their compensation for services.

Movements in reserve
Movements in each class of reserve during the current and previous financial year are set out below:

Consolidated	Share-based payment reserve $'000
Balance at 1 July 2024	-
Options issued	32
Balance at 30 June 2025	32
Options issued	226
Balance at 30 June 2026	258

For personal use only

For personal use only

Note 24. Dividends

Dividends
Dividends paid during the financial year were as follows:

	Consolidated 2026 $'000	Consolidated 2025 $'000
Final unfranked dividend for the year ended 30 June 2026 of 0 cents (2025: paid 2 cents final unfranked dividend for the year ended 30 June 2024) per ordinary share	-	976

Note 25. Financial instruments

Financial risk management objectives

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk, price risk and interest rate risk), credit risk and liquidity risk. The Group's overall risk management program focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the financial performance of the Group. The Group uses different methods to measure different types of risk to which it is exposed. These methods include sensitivity analysis in the case of interest rate, foreign exchange and other price risks, and ageing analysis for credit risk.

Risk management is carried out by senior finance executives ('finance') under policies approved by the Board of Directors ('the Board'). These policies include identification and analysis of the risk exposure of the Group and appropriate procedures, controls and risk limits. Finance identifies, evaluates and hedges financial risks within the Group's operating units. Finance reports to the Board on a monthly basis.

Market risk

Foreign currency risk
The Group is not exposed to significant foreign currency risk.

Price risk
The Group is not exposed to any significant price risk.

Interest rate risk
The Group’s primary interest rate risk arises from long-term borrowings with floating interest rates, which expose the Group to cash flow interest rate risk. Borrowings issued at variable rates expose the Group to cash flow sensitivity, whereas fixed-rate borrowings expose the Group to fair value interest rate risk.

Consequently, fluctuations in market interest rates will directly impact the Group’s interest expense and cash flows. A hypothetical 100 basis point increase or decrease in the interest rates applicable to its floating-rate debt would result in an approximate increase or decrease of $56,500 in annual interest expense, assuming constant borrowing levels.

Management monitors interest rate exposure on an ongoing basis. Based on the simulation performed a 100 basis point change in market interest rates would not have a material impact on the Group’s net income or equity for the year ended 30 June 2026.

Note 25. Financial instruments (continued)

As at the reporting date, the Group had the following variable rate borrowings outstanding:

Consolidated	2026 Weighted average interest rate %	2026 Balance $'000	2025 Weighted average interest rate %	2025 Balance $'000
Bank loans	4.36%	5,650	-	-
Net exposure to cash flow interest rate risk		5,650		-

An analysis by remaining contractual maturities is shown in 'liquidity and interest rate risk management' below.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Group. The Group has a strict code of credit, including obtaining agency credit information, confirming references and setting appropriate credit limits. The Group obtains guarantees where appropriate to mitigate credit risk. The maximum exposure to credit risk at the reporting date to recognised financial assets is the carrying amount, net of any provisions for impairment of those assets, as disclosed in the statement of financial position and notes to the financial statements. The Group does not hold any collateral.

The Group trades with a number of types of customers, the main ones being:

- Incorporated companies;
- Research institutes (both private and academic); and
- Cord blood customers.

Incorporated Companies

The Group trades with recognised, publicly listed companies and large unlisted proprietary companies and as such collateral is not requested nor is it the Group's policy to securitise its trade and other receivables.

Research institutes (both private and academic)

The Group also trades with research institutes that are either publicly, privately or government owned along with recognised universities. Such customers are subject to credit search and collateral is not requested nor is it the Group’s policy to securitise its trade and other receivables.

Cord blood customers

All cord blood customers sign a formal agreement and prepay for their storage charges.

The Group does not offer individuals a trade on credit term. Credit risk limits are remote and regularly monitored. There are no transactions that are not denominated in the functional currency of the Group.

Generally, trade receivables are written off when there is no reasonable expectation of recovery. Indicators of this include the failure of a debtor to engage in a repayment plan, no active enforcement activity and a failure to make contractual payments for a period greater than 1 year.

Liquidity risk

Vigilant liquidity risk management requires the Group to maintain sufficient liquid assets (mainly cash and cash equivalents) and available borrowing facilities to be able to pay debts as and when they become due and payable.

For personal use only

For personal use only

Note 25. Financial instruments (continued)

The Group manages liquidity risk by maintaining adequate cash reserves and available borrowing facilities by continuously monitoring actual and forecast cash flows and matching the maturity profiles of financial assets and liabilities.

Remaining contractual maturities
The following tables detail the Group's remaining contractual maturity for its financial instrument liabilities. The tables have been drawn up based on the discounted cash flows of financial liabilities based on the earliest date on which the financial liabilities are required to be paid. The tables include both interest and principal cash flows disclosed as remaining contractual maturities and therefore these totals may differ from their carrying amount in the statement of financial position.

Consolidated - 2026	Weighted average interest rate %	1 year or less $'000	Between 1 and 2 years $'000	Between 2 and 5 years $'000	Over 5 years $'000	Remaining contractual maturities $'000
Non-derivatives						
Non-interest bearing						
Trade payables	-	888	-	-	-	888
Other payables	-	834	-	-	-	834
	-	-	-	-	-	-
Interest-bearing - variable						
Bank loans	-	-	-	5,650	-	5,650
Interest-bearing - fixed rate						
Lease liability	5.50%	220	242	558	1,048	2,068
Total non-derivatives		1,942	242	6,208	1,048	9,440

Consolidated - 2025	Weighted average interest rate %	1 year or less $'000	Between 1 and 2 years $'000	Between 2 and 5 years $'000	Over 5 years $'000	Remaining contractual maturities $'000
Non-derivatives						
Non-interest bearing						
Trade payables	-	1,070	-	-	-	1,070
Other payables	-	661	-	-	-	661
	-	-	-	-	-	-
Interest-bearing - fixed rate						
Lease liability	5.50%	199	220	800	1,048	2,267
Total non-derivatives		1,930	220	800	1,048	3,998

The cash flows in the maturity analysis above are not expected to occur significantly earlier than contractually disclosed above.

Fair value of financial instruments
Unless otherwise stated, the carrying amounts of financial instruments reflect their fair value.

For personal use only

Note 26. Key management personnel disclosures

Compensation
The aggregate compensation made to directors and other members of key management personnel of the Group is set out below:

	Consolidated 2026 $	Consolidated 2025 $
Short-term employee benefits (1)	834,590	895,561
Post-employment benefits	115,103	129,665
Share-based payments	174,840	21,592
Other cash benefits (2)	15,204	9,874
	1,139,737	1,056,692

(1) Salary and director fees paid and accrued for the financial year ended 30 June 2026
(2) Other cash benefits were bonuses accrued but not yet paid as at 30 June 2026

Note 27. Remuneration of auditors

During the financial year the following fees were paid or payable for services provided by Forvis Mazars Audit & Assurance Pty Limited, the auditor of the Company:

	Consolidated 2026 $	Consolidated 2025 $
Audit services - Forvis Mazars Audit & Assurance Pty Limited		
Audit or review of the financial statements	78,000	76,500

Note 28. Contingent liabilities

Bank guarantees of $198,000 (2025: $198,000) exist at year-end in respect of the Group's obligations under the premises lease arrangements.

Note 29. Commitments

The Group did not have any commitments as at 30 June 2026 (2025: none).

Note 30. Related party transactions

Parent entity
Cryosite Limited is the parent entity.

Subsidiary
Interests in subsidiary are set out in note 32.

Key management personnel
Disclosures relating to key management personnel are set out in note 26 and the remuneration report included in the directors' report.

Transactions with related parties
There were no transactions with related parties during the current and previous financial year.

Receivable from and payable to related parties
There were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Note 30. Related party transactions (continued)

Loans to/from related parties
There were no loans to or from related parties at the current and previous reporting date.

Note 31. Parent entity information

Set out below is the supplementary information about the parent entity.

Statement of profit or loss and other comprehensive income

	Parent 2026 $'000	2025 $'000
Profit after income tax	2,273	1,884
Total comprehensive income	2,273	1,884

Statement of financial position

	Parent 2026 $'000	2025 $'000
Total current assets	6,143	8,869
Total assets	23,924	19,464
Total current liabilities	4,895	4,519
Total liabilities	19,036	17,075
Equity		
Issued capital	3,538	3,538
Share-based payments reserve	258	32
Retained profits/(accumulated losses)	1,092	(1,181)
Total equity	4,888	2,389

Guarantees entered into by the parent entity in relation to the debts of its subsidiaries
The parent entity provided a Guarantee and Indemnity to its subsidiary Cryosite Property Pty Ltd for the $5,650,000 mortgage facility with NAB bank.

Contingent liabilities
The parent entity had contingent liabilities same as mentioned in note 28.

Capital commitments - Property, plant and equipment
The parent entity had capital commitments same as mentioned in note 29.

Material accounting policy information
The accounting policies of the parent entity are consistent with those of the Group, as disclosed in note 2, except for the following:

- Investments in subsidiaries are accounted for at cost, less any impairment, in the parent entity.
- Dividends received from subsidiaries are recognised as other income by the parent entity and its receipt may be an indicator of an impairment of the investment.

For personal use only

For personal use only

Note 32. Interests in subsidiary

The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:

Name	Principal place of business / Country of incorporation	Ownership interest 2026 %	Ownership interest 2025 %
Cryosite Distribution Pty Limited	Australia	100%	100%
Cryosite Property Pty Ltd	Australia	100%	-

Note 33. Cash flow information

Reconciliation of profit after income tax to net cash from operating activities

	Consolidated 2026 $'000	Consolidated 2025 $'000
Profit after income tax expense for the year	2,235	1,884
Adjustments for:		
Depreciation and amortisation expense	912	871
Foreign exchange differences	3	-
Interest received	(119)	(166)
Interest and other finance costs	336	150
Change in operating assets and liabilities:		
Increase in trade and other receivables	(292)	(865)
Decrease in customer acquisition and fulfilment costs	1,038	1,126
Decrease in deferred tax assets	40	41
Decrease in contract liabilities	(1,631)	(1,791)
Decrease in other assets	70	16
Increase in contract liabilities	124	309
Increase/(decrease) in provision for income tax	122	(52)
Increase in employee benefits	54	24
(Decrease)/increase in trade and other creditors	(5)	581
Decrease in other liabilities	(67)	(64)
Net cash from operating activities	2,820	2,064

Changes in liabilities arising from financing activities

Consolidated	Borrowings $'000	Lease liabilities $'000	Total $'000
Balance at 1 July 2024	-	2,445	2,445
Net cash used in financing activities	-	(311)	(311)
Accretion of interest	-	130	130
Lease other	-	3	3
Balance at 30 June 2025	-	2,267	2,267
Net cash from/(used in) financing activities	5,494	(324)	5,170
Accretion of interest	156	120	276
Balance at 30 June 2026	5,650	2,063	7,713

For personal use only

Note 34. Share-based payments

Long Term Incentive Plan: Employee Option Plan (EOP)

The Employee Option Plan (EOP) the share option plan has been established by the Group and approved by shareholders at a general meeting, whereby the Group may, at the discretion of the Remuneration and Nomination Committee, grant options over ordinary shares in the Company to certain key management personnel of the Group. The options are issued for nil consideration and are granted in accordance with performance guidelines established by the Remuneration and Nomination Committee. The options are convertible to ordinary shares on the satisfaction of VWAP exceeding the exercise price for 10 consecutive business days and time vesting conditions which vary between option tranches.

Set out below are summaries of options granted under the plan:

	Number of options 2026	Weighted average exercise price 2026	Number of options 2025	Weighted average exercise price 2025
Outstanding at the beginning of the financial year	1,000,000	$1.06	-	$0.00
Granted	1,666,666	$1.22	1,000,000	$1.06
Forfeited	-	$0.00	-	$0.00
Exercised	-	$0.00	-	$0.00
Expired	-	$0.00	-	$0.00
Outstanding at the end of the financial year	2,666,666	$1.16	1,000,000	$1.06
Exercisable at the end of the financial year	-	$0.00	-	$0.00

2026

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
17/03/2025	17/03/2032	$0.90	200,000	-	-	-	200,000
17/03/2025	17/03/2032	$0.90	200,000	-	-	-	200,000
17/03/2025	17/03/2032	$1.10	150,000	-	-	-	150,000
17/03/2025	17/03/2032	$1.10	150,000	-	-	-	150,000
17/03/2025	17/03/2032	$1.20	100,000	-	-	-	100,000
17/03/2025	17/03/2032	$1.20	100,000	-	-	-	100,000
17/03/2025	17/03/2032	$1.30	50,000	-	-	-	50,000
17/03/2025	17/03/2032	$1.30	50,000	-	-	-	50,000
16/10/2025	16/10/2030	$0.90	-	200,000	-	-	200,000
16/10/2025	16/10/2030	$0.90	-	200,000	-	-	200,000
16/10/2025	16/10/2030	$1.10	-	150,000	-	-	150,000
16/10/2025	16/10/2030	$1.10	-	150,000	-	-	150,000
16/10/2025	16/10/2030	$1.20	-	100,000	-	-	100,000
16/10/2025	16/10/2030	$1.20	-	100,000	-	-	100,000
16/10/2025	16/10/2030	$1.30	-	50,000	-	-	50,000
16/10/2025	16/10/2030	$1.30	-	50,000	-	-	50,000
18/03/2026	26/02/2031	$1.30	-	133,333	-	-	133,333
18/03/2026	26/02/2031	$1.30	-	133,333	-	-	133,333
18/03/2026	26/02/2031	$1.50	-	100,000	-	-	100,000
18/03/2026	26/02/2031	$1.50	-	100,000	-	-	100,000
18/03/2026	26/02/2031	$1.60	-	66,667	-	-	66,667
18/03/2026	26/02/2031	$1.60	-	66,667	-	-	66,667
18/03/2026	26/02/2031	$1.70	-	33,333	-	-	33,333
18/03/2026	26/02/2031	$1.70	-	33,333	-	-	33,333
			1,000,000	1,666,666	-	-	2,666,666

Note 34. Share-based payments (continued)

Weighted average exercise price			$1.06	$1.22	$0.00	$0.00	$1.16

2025

Grant date	Expiry date	Exercise price	Balance at the start of the year	Granted	Exercised	Expired/ forfeited/ other	Balance at the end of the year
17/03/2025	17/03/2032	$0.90	-	200,000	-	-	200,000
17/03/2025	17/03/2032	$0.90	-	200,000	-	-	200,000
17/03/2025	17/03/2032	$1.10	-	150,000	-	-	150,000
17/03/2025	17/03/2032	$1.10	-	150,000	-	-	150,000
17/03/2025	17/03/2032	$1.20	-	100,000	-	-	100,000
17/03/2025	17/03/2032	$1.20	-	100,000	-	-	100,000
17/03/2025	17/03/2032	$1.30	-	50,000	-	-	50,000
17/03/2025	17/03/2032	$1.30	-	50,000	-	-	50,000
			-	1,000,000	-	-	1,000,000

The weighted average exercise price of options during the financial year was $1.16 (2025: $1.06)

The weighted average remaining contractual life of options outstanding at the end of the financial year was 5 years (2025: 3 years).

Total share-based payment expenses recognised in the profit and loss:

	Consolidated 2026	Consolidated 2025
Options	226	32

Accounting policy for share-based payments
Equity-settled and cash-settled share-based compensation benefits are provided to employees.

Equity-settled transactions are awards of shares, or options over shares, that are provided to employees in exchange for the rendering of services. Cash-settled transactions are awards of cash for the exchange of services, where the amount of cash is determined by reference to the share price.

The cost of equity-settled transactions are measured at fair value on grant date. Fair value is independently determined using the Black-Scholes option pricing model that takes into account the exercise price, the term of the option, the impact of dilution, the share price at grant date and expected price volatility of the underlying share, the expected dividend yield and the risk free interest rate for the term of the option, together with non-vesting conditions that do not determine whether the Group receives the services that entitle the employees to receive payment. No account is taken of any other vesting conditions.

The cost of equity-settled transactions are recognised as an expense with a corresponding increase in equity over the vesting period. The cumulative charge to profit or loss is calculated based on the grant date fair value of the award, the best estimate of the number of awards that are likely to vest and the expired portion of the vesting period. The amount recognised in profit or loss for the period is the cumulative amount calculated at each reporting date less amounts already recognised in previous periods.

Market conditions are taken into consideration in determining fair value. Therefore any awards subject to market conditions are considered to vest irrespective of whether or not that market condition has been met, provided all other conditions are satisfied.

If equity-settled awards are modified, as a minimum an expense is recognised as if the modification has not been made. An additional expense is recognised, over the remaining vesting period, for any modification that increases the total fair value of the share-based compensation benefit as at the date of modification.

For personal use only

Note 34. Share-based payments (continued)

If the non-vesting condition is within the control of the Group or employee, the failure to satisfy the condition is treated as a cancellation. If the condition is not within the control of the Group or employee and is not satisfied during the vesting period, any remaining expense for the award is recognised over the remaining vesting period, unless the award is forfeited.

If equity-settled awards are cancelled, it is treated as if it has vested on the date of cancellation, and any remaining expense is recognised immediately. If a new replacement award is substituted for the cancelled award, the cancelled and new award is treated as if they were a modification.

Note 35. Events after the reporting period

No matter or circumstance has arisen since 30 June 2026 that has significantly affected, or may significantly affect the Group's operations, the results of those operations, or the Group's state of affairs in future financial years.

For personal use only

Cryosite Limited
Consolidated entity disclosure statement
As at 30 June 2026

Entity name	Entity type	Place formed / Country of incorporation	Ownership interest%	Tax residency
Cryosite Distribution Pty Limited	Body Corporate	Australia	100%	Australia
Cryosite Property Pty Ltd	Body Corporate	Australia	100%	Australia

For personal use only

Cryosite Limited
Directors' declaration
30 June 2026

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with IFRS Accounting Standards as issued by the International Accounting Standards Board as described in note 2 to the financial statements;
- the attached financial statements and notes give a true and fair view of the Group's financial position as at 30 June 2026 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable; and
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors

Mark Kerr

Mark Kerr
Non-Executive Chairman

18 August 2026

For personal use only

forvis mazars

5/600 Bourke Street
Melbourne Vic 3000
Australia
Tel +61 3 9252 0800
forvismazars.com/au

For personal use only

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CRYOSITE LIMITED AND ITS CONTROLLED ENTITIES

Report on the Financial Report

Opinion

We have audited the accompanying consolidated financial report of Cryosite Limited (the "Company") and the entities it controlled (the "Group"), which comprises the consolidated statement of financial position as at 30 June 2026 and the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying consolidated financial report of the Group is in accordance with the *Corporations Act 2001*, including:

(i) giving a true and fair view of the consolidated entity's financial position as at 30 June 2026 and of its financial performance for the year then ended; and
(ii) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial report for the current year. This matter was addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, but we do not provide a separate opinion on the matter. For the matter below, our description of how our audit addressed the matter is provided in that context.

For personal use only

We have fulfilled the responsibilities described in the Auditor's Responsibility section of our report, including in relation to the matter. Accordingly, our audit included the performance of procedures designed to respond to our assessment of the risks of material misstatement of the financial statements. The results of our audit procedures, including the procedures performed to address the matter below, provide the basis for our audit opinion on the accompanying financial report.

Key Audit Matter	How our audit addressed the matter
Revenue recognition – deferred revenue and revenue cut-off Cryosite Limited provides specialised outsourced clinical trials logistic services. The timing of revenue recognition is critical due to the nature of long-term storage contracts and service agreements with customers. A significant portion of the company's revenue includes upfront payments for services to be delivered over time, creating deferred revenue liabilities. Revenue is recognised over the period in which the services are delivered, often based on the passage of time or the completion of performance obligations. Judgement is required to determine: • The appropriate recognition pattern of revenue over time; • The allocation of contract revenue to performance obligations; • The completeness and accuracy of deferred revenue balances at year-end; and • The cut-off of revenue close to balance date. Given the level of management judgement and the risk of misstated revenue due to inappropriate cut-off or incorrect deferral of income, we determined this to be a key audit matter.	Our audit procedures included, among others: • Evaluating the company's revenue recognition policies for compliance with AASB 15 Revenue from Contracts with Customers; • Assessing the design and operating effectiveness of relevant controls over revenue recognition and deferred revenue accounting; • Testing a sample of customer contracts to evaluate management's identification of performance obligations and the timing of revenue recognition; • Performing substantive analytical procedures and detailed testing of revenue recognised near year-end to ensure revenue was recorded in the appropriate period (cut-off testing); • Reviewing deferred revenue balances and assessing whether revenue was deferred appropriately in accordance with the underlying contracts; • Testing journal entries impacting revenue and deferred revenue for unusual or inappropriate items. We also assessed the adequacy of the financial statement disclosures relating to revenue recognition and deferred revenue.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the annual report for the year ended 30 June 2026 but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there

is a material misstatement of the other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Report

The directors of the Group are responsible for the preparation of:

(i) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with the Australian Accounting Standards and the *Corporations Act 2001*; and

(ii) the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and

for such internal control as the directors determine is necessary to enable the preparation of:

(iii) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and

(iv) the consolidated entity disclosure statement that is true and correct and is free of material misstatement, whether due to fraud or error

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgment and maintain professional scepticism throughout the audit.

A further description of our responsibilities for the audit of the financial report is located at the Auditing and Assurance Standards Board website at: AUASB Auditors Responsibilities Group Listed. This description forms part of our auditor's report.

For personal use only

Opinion on the Remuneration Report

We have audited the Remuneration Report for the year ended 30 June 2026 as outlined on pages 14 to 21 of the financial report.

In our opinion, the Remuneration Report of Cryosite Limited for the year ended 30 June 2026, complies with section 300A of the *Corporations Act 2001*.

Responsibilities

The directors of the company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.



Forvis Mazars Audit & Assurance Pty Ltd



Alexis Aupied
Director
Melbourne

18 August 2026

For personal use only

Cryosite Limited
Shareholder information
30 June 2026

The shareholder information set out below was applicable as at 5 August 2026.

Distribution of equitable securities

Analysis of number of equitable security holders by size of holding:

	Ordinary shares		Options over ordinary shares	
	Number of holders	% of total shares issued	Number of holders	% of total shares issued
1 to 1,000	64	0.04	-	-
1,001 to 5,000	215	1.54	-	-
5,001 to 10,000	56	0.94	-	-
10,001 to 100,000	98	6.44	-	-
100,001 and over	39	91.04	-	-
	472	100.00	-	-
Holding less than a marketable parcel	-	-	-	-

Equity security holders

Twenty largest quoted equity security holders

The names of the twenty largest security holders of quoted equity securities are listed below:

	Ordinary shares	
	Number held	% of total shares issued
DALTONVALE PROPRIETARY LIMITED <KROGER PROPERTY INVEST A/C>	9,731,663	19.94
MR MARK GREGORY KERR & MRS LINDA MARIE KERR <LINDMARK INV STAFF S/F A/C>	7,231,453	14.82
LAURIE THOMAS FAMILY NOMINEES PTY LTD <THOMAS FAMILY S/F A/C>	4,000,000	8.20
MR GARY GRIFFITH ROBINS & MR ALLAN JAMES ROBINS <ROBINS SF A/C>	3,733,511	7.65
BNP PARIBAS NOMS PTY LTD	3,312,039	6.79
MR ALISTAIR DAVID STRONG	2,150,000	4.40
PARADYCE PTY LTD (THE PARADYCE A/C)	2,075,000	4.25
MARENSA PTY LTD (STEWART SUPER A/C)	2,000,000	4.10
BNP PARIBAS NOMINEES PTY LTD (IB AU NOMS RETAILCLIENT)	1,190,072	2.44
THIRTY SIXTH VILMAR PTY LTD	903,000	1.85
BELL POTTER NOMINEES LTD <BB NOMINEES A/C>	705,982	1.45
BFA SUPER PTY LTD <GDN SUPER FUND A/C>	700,000	1.43
GINGA PTY LTD <THOMAS G KLINGER FAMILY A/C>	563,957	1.16
MR GARY GRIFFITH ROBINS	534,813	1.10
GINGA PTY LTD	504,000	1.03
H F A ADMINISTRATION PTY LIMITED <SUPER FUND A/C>	480,000	0.98
LION NOMINEES PTY LTD <JB PARNCUTT FAMILY SUPER A/C>	442,635	0.91
SUNNYIT PTY LTD <SUNNYIT SUPERANNUATION A/C>	375,000	0.77
MRS JANE SUSAN MILLIKEN	350,917	0.72
JAWESS PTY LTD <KENT FAMILY SUPER FUND A/C>	309,338	0.63
	41,293,380	84.62

Unquoted equity securities

There are no unquoted equity securities.

For personal use only

Cryosite Limited
Shareholder information
30 June 2026

Substantial holders

Substantial holders in the Company are set out below:

	Ordinary shares	
	Number held	% of total shares issued
ANDREW KROGER and other entities	13,043,702	26.70
MR MARK GREGORY KERR & MRS LINDA MARIE KERR	9,306,453	19.10
MR GARY GRIFFITH ROBINS & MR ALLAN JAMES ROBINS	4,377,408	8.97
LAURIE THOMAS FAMILY NOMINEES PTY LTD	4,000,000	8.20

Voting rights

The voting rights attached to ordinary shares are set out below:

Ordinary shares
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

There are no other classes of equity securities.

For personal use only

For personal use only

About Cryosite

Cryosite is a unique Australian company and a world-class specialist in providing outsourced clinical trial and biological depot services.

Established in 2000, Cryosite is highly experienced in clinical trial logistics. Our team is comprised of highly qualified scientists and clinical trials experts who ensure complex clinical trials are conducted with seamless efficiency and safety.

We manage the importation, receipt, storage, distribution and reverse logistics of specialized ambient, cold, frozen, ultra-frozen, liquid nitrogen clinical trial, pharmaceutical and biological products. Cryosite's third party depot services are professional, reliable and compliant; our people are experts in their respective fields and are approachable, ethical and responsive to clients' needs.

To learn more, please visit our website or Cryosite's Investor Hub.

Ferndell Street Facility (Headquarters)

- 13a Ferndell Street, South Granville, NSW, 2142
- Total Usage Area :2100sqm (Building Area: ~1,800sqm + 300sqm Mezzanine extn)
- GMP, GWP licenced
- Services include Clinical Trial and Biological:
    - Storage
    - Importation
    - Receipt
    - Labelling
    - Distribution
    - Secondary packaging
    - Reverse logistics
    - Expiry extension

Adderley Street Facility

- 100-104 Adderley Street West, Auburn, NSW, 2144
- ~15 minutes' drive from Ferndell Street
- Building Area: ~2,100sqm (clearance 9.1m)
- Services include:
    - Clinical Trial and Biological service expansion
    - Medical devices
    - Reverse logistics
    - Pallet storage
    - Talk to us about your requirements - contact@cryosite.com



